<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523420308084</prism:url><dc:identifier>doi:10.1016/j.ejmech.2020.112836</dc:identifier><eid>1-s2.0-S0223523420308084</eid><prism:doi>10.1016/j.ejmech.2020.112836</prism:doi><pii>S0223-5234(20)30808-4</pii><dc:title>An electrophilic warhead library for mapping the reactivity and accessibility of tractable cysteines in protein kinases </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>207</prism:volume><prism:startingPage>112836</prism:startingpage><prism:pageRange>112836</prism:pagerange><articleNumber>112836</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2020-12-01</prism:coverdate><prism:coverDisplayDate>1 December 2020</prism:coverdisplaydate><prism:copyright>© 2020 The Author(s). Published by Elsevier Masson SAS.</prism:copyright><prism:publisher>The Author(s). Published by Elsevier Masson SAS.</prism:publisher><dc:creator>Petri, László</dc:creator><dc:creator>Egyed, Attila</dc:creator><dc:creator>Bajusz, Dávid</dc:creator><dc:creator>Imre, Tímea</dc:creator><dc:creator>Hetényi, Anasztázia</dc:creator><dc:creator>Martinek, Tamás</dc:creator><dc:creator>Ábrányi-Balogh, Péter</dc:creator><dc:creator>Keserű, György M.</dc:creator><dc:description>
                  Targeted covalent inhibitors represent a viable strategy to block protein kinases involved in different disease pathologies. Although a number of computational protocols have been published for identifying druggable cysteines, experimental approaches are limited for mapping the reactivity and accessibility of these residues. Here, we present a ligand based approach using a toolbox of fragment-sized molecules with identical scaffold but equipped with diverse covalent warheads. Our library represents a unique opportunity for the efficient integration of warhead-optimization and target-validation into the covalent drug development process. Screening this probe kit against multiple kinases could experimentally characterize the accessibility and reactivity of the targeted cysteines and helped to identify suitable warheads for designed covalent inhibitors. The usefulness of this approach has been confirmed retrospectively on Janus kinase 3 (JAK3). Furthermore, representing a prospective validation, we identified Maternal embryonic leucine zipper kinase (MELK), as a tractable covalent target. Covalently labelling and biochemical inhibition of MELK would suggest an alternative covalent strategy for MELK inhibitor programs.
               </dc:description><openaccess>1</openaccess><openaccessArticle>true</openaccessarticle><openaccessType>Full</openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName>Hungary Institutes</openaccesssponsorname><openaccessSponsorType>FundingBody</openaccesssponsortype><openaccessUserLicense>http://creativecommons.org/licenses/by-nc-nd/4.0/</openaccessuserlicense><dcterms:subject>Warhead selection</dcterms:subject><dcterms:subject>Kinase cysteome profiling</dcterms:subject><dcterms:subject>Targeted covalent inhibitors</dcterms:subject><dcterms:subject>Small-molecule kinase inhibitors</dcterms:subject><dcterms:subject>JAK3</dcterms:subject><dcterms:subject>MELK</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523420308084" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523420308084" rel="scidir"/></link></coredata><objects><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="602" height="320" size="36516">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="378" height="418" size="52841">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="492" height="359" size="30971">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="308" height="200" size="30221">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="580" height="149" size="36643">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="378" height="303" size="34114">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="602" height="409" size="61581">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="117" size="5070">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="148" height="164" size="12624">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="160" size="5841">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="142" size="19408">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="56" size="7816">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="204" height="164" size="11151">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="149" size="11610">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2666" height="1419" size="292003">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-sc1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1673" height="1850" size="570372">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2177" height="1587" size="237818">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1363" height="886" size="240480">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2568" height="660" size="352751">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1673" height="1342" size="306869">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2666" height="1812" size="507519">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Microsoft Word file" mimetype="application/word" size="863085">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-mmc1.docx?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="662414">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420308084-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85091119878</scopus-id><scopus-eid>2-s2.0-85091119878</scopus-eid><pubmed-id>32971426</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85091119878" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
         <xocs:ssid type="oa">90</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20200912">2020-09-12</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20200912">2020-09-12</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20200922">2020-09-22</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20200922">2020-09-22</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2020-11-04T16:42:27</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523420308084</xocs:eid>
      <xocs:pii-formatted>S0223-5234(20)30808-4</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523420308084</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2020.112836</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523420X00201</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20201105">2020-11-05T00:58:14.921246Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20201201</xocs:date-search-begin>
      <xocs:year-nav>2020</xocs:year-nav>
      <xocs:indexeddate epoch="1599923926">2020-09-12T15:18:46.909587Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid fundingbodyid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight oauserlicense openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder sponsoredaccesstype srctitle srctitlenorm srctype ssids alllist content oa subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast grantnumber grantsponsor grantsponsorid highlightsabst orcid primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type>
      <xocs:funding-body-id>EISZ</xocs:funding-body-id>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>207</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>207</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 207</xocs:vol-iss-suppl-text>
      <xocs:sort-order>57</xocs:sort-order>
      <xocs:first-fp>112836</xocs:first-fp>
      <xocs:article-number>112836</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>112836</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20201201</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>1 December 2020</xocs:cover-date-text>
      <xocs:cover-date-start>2020-12-01</xocs:cover-date-start>
      <xocs:cover-date-year>2020</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Full papers</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2020 The Author(s). Published by Elsevier Masson SAS.</xocs:copyright-line>
      <xocs:normalized-article-title>ELECTROPHILICWARHEADLIBRARYFORMAPPINGREACTIVITYACCESSIBILITYTRACTABLECYSTEINESINPROTEINKINASES</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>PETRI</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>L</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Design and characterization of the covalent fragment library</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Mapping the reactivity of kinase cysteines</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Retrospective validation on JAK3</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Prospective validation on MELK</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusion</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Experimental section</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Instruments</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Local electrophilicity (local EPI) calculations</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>GSH reactivity assay</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Oligopeptide selectivity assay</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>Kinase activity assays</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>JAK3 proteomics MS/MS</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.7</xocs:item-toc-label>
               <xocs:item-toc-section-title>NMR measurements for MELK</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.8</xocs:item-toc-label>
               <xocs:item-toc-section-title>Covalent docking</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.9</xocs:item-toc-label>
               <xocs:item-toc-section-title>Synthesis</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.9.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure of Suzuki coupling [<ce:cross-ref id="crosref0470" refid="bib52">52</ce:cross-ref>]</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.9.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>3-(7<ce:italic>H</ce:italic>-Pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidin-4-yl)benzaldehyde (25)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.9.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>3-(7<ce:italic>H</ce:italic>-Pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidin-4-yl)aniline (26) [<ce:cross-ref id="optgiatMgXJWY" refid="bib52">52</ce:cross-ref>]</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.9.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>3-(3-(7<ce:italic>H</ce:italic>-Pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidin-4-yl)phenyl)-2-cyanoacrylamide (30)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.9.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>N</ce:italic>-(3-(7<ce:italic>H</ce:italic>-Pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidin-4-yl)phenyl)-2-bromopropanamide (31)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.9.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>N</ce:italic>-(3-(7<ce:italic>H</ce:italic>-Pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidin-4-yl)phenyl)acetamide (32)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Author contributions</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgement</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>BAUER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1061</xocs:ref-first-fp>
            <xocs:ref-last-lp>1073</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>ABDELDAYEM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>MILLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>528</xocs:ref-first-fp>
            <xocs:ref-last-lp>538</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>COHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>E127</xocs:ref-first-fp>
            <xocs:ref-last-lp>E130</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>GRANT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1163</xocs:ref-first-fp>
            <xocs:ref-last-lp>1177</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>GHARWAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>209</xocs:ref-first-fp>
            <xocs:ref-last-lp>227</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>SANTOS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>19</xocs:ref-first-fp>
            <xocs:ref-last-lp>34</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>ZHAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>727</xocs:ref-first-fp>
            <xocs:ref-last-lp>735</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>YVER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1165</xocs:ref-first-fp>
            <xocs:ref-last-lp>1170</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>KNIGHT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>130</xocs:ref-first-fp>
            <xocs:ref-last-lp>137</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>BRZEZNIAK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>247</xocs:ref-first-fp>
            <xocs:ref-last-lp>253</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>WU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>21</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>PAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>58</xocs:ref-first-fp>
            <xocs:ref-last-lp>61</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>BAILLIE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>13408</xocs:ref-first-fp>
            <xocs:ref-last-lp>13421</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>SHANNON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>18</xocs:ref-first-fp>
            <xocs:ref-last-lp>26</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>LONSDALE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>3124</xocs:ref-first-fp>
            <xocs:ref-last-lp>3137</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>GEHRINGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>5673</xocs:ref-first-fp>
            <xocs:ref-last-lp>5724</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1486</xocs:ref-first-fp>
            <xocs:ref-last-lp>1500</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>DU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1258</xocs:ref-first-fp>
            <xocs:ref-last-lp>1260</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>GERSCH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>659</xocs:ref-first-fp>
            <xocs:ref-last-lp>682</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>MCGREGOR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>3178</xocs:ref-first-fp>
            <xocs:ref-last-lp>3183</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>WEERAPANA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>790</xocs:ref-first-fp>
            <xocs:ref-last-lp>795</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>BACKUS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>CURRENTTOPICSINMICROBIOLOGYIMMUNOLOGY</xocs:ref-normalized-srctitle>
            <xocs:ref-normalized-article-title>APPLICATIONSREACTIVECYSTEINEPROFILING</xocs:ref-normalized-article-title>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>353</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>SHIRAIWA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>970</xocs:ref-first-fp>
            <xocs:ref-last-lp>985</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>AWOONORWILLIAMS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1935</xocs:ref-first-fp>
            <xocs:ref-last-lp>1946</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>ZHAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>2879</xocs:ref-first-fp>
            <xocs:ref-last-lp>2889</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>6553</xocs:ref-first-fp>
            <xocs:ref-last-lp>6560</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1453</xocs:ref-first-fp>
            <xocs:ref-last-lp>1460</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>MURRAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>153</xocs:ref-first-fp>
            <xocs:ref-last-lp>163</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>NARAYSZABO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>829</xocs:ref-first-fp>
            <xocs:ref-last-lp>847</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>COHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>1318</xocs:ref-first-fp>
            <xocs:ref-last-lp>1321</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>LEPROULT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1347</xocs:ref-first-fp>
            <xocs:ref-last-lp>1355</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>146</xocs:ref-first-fp>
            <xocs:ref-last-lp>159</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>AWOONORWILLIAMS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1664</xocs:ref-first-fp>
            <xocs:ref-last-lp>1675</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>ERLANSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>605</xocs:ref-first-fp>
            <xocs:ref-last-lp>619</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>KEELEY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>KRENSKE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>11726</xocs:ref-first-fp>
            <xocs:ref-last-lp>11733</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>FLANAGAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>10072</xocs:ref-first-fp>
            <xocs:ref-last-lp>10079</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>CEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>9171</xocs:ref-first-fp>
            <xocs:ref-last-lp>9178</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>PETRI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>115357</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>FERENCZY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1039</xocs:ref-first-fp>
            <xocs:ref-last-lp>1045</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>CHATTARAJ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>2065</xocs:ref-first-fp>
            <xocs:ref-last-lp>2091</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>ABRANYIBALOGH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>94</xocs:ref-first-fp>
            <xocs:ref-last-lp>107</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>MANNING</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>1912</xocs:ref-first-fp>
            <xocs:ref-last-lp>1934</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>CHARTIER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>e126</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>VASUDEVAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>PROGRESSINMEDICINALCHEMISTRY</xocs:ref-normalized-srctitle>
            <xocs:ref-normalized-article-title>COVALENTBINDERSINDRUGDISCOVERY</xocs:ref-normalized-article-title>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>GOEDKEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>4573</xocs:ref-first-fp>
            <xocs:ref-last-lp>4589</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>TAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>6589</xocs:ref-first-fp>
            <xocs:ref-last-lp>6606</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref50">
            <xocs:ref-normalized-surname>KEMPSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>4622</xocs:ref-first-fp>
            <xocs:ref-last-lp>4625</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref51">
            <xocs:ref-normalized-surname>TELLIEZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>3442</xocs:ref-first-fp>
            <xocs:ref-last-lp>3451</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref52">
            <xocs:ref-normalized-surname>THORARENSEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1971</xocs:ref-first-fp>
            <xocs:ref-last-lp>1993</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref53">
            <xocs:ref-normalized-surname>FORSTER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>4229</xocs:ref-first-fp>
            <xocs:ref-last-lp>4237</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref54">
            <xocs:ref-normalized-surname>HE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>343</xocs:ref-first-fp>
            <xocs:ref-last-lp>358</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref55">
            <xocs:ref-normalized-surname>GUNASEKAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>12351</xocs:ref-first-fp>
            <xocs:ref-last-lp>12358</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref56">
            <xocs:ref-normalized-surname>LONDON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1066</xocs:ref-first-fp>
            <xocs:ref-last-lp>1072</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref57">
            <xocs:ref-normalized-surname>REN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref58">
            <xocs:ref-normalized-surname>CHLENSKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>507</xocs:ref-first-fp>
            <xocs:ref-last-lp>516</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref59">
            <xocs:ref-normalized-surname>CIGLIANO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref60">
            <xocs:ref-normalized-surname>MEEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>58</xocs:ref-first-fp>
            <xocs:ref-last-lp>69</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref61">
            <xocs:ref-normalized-surname>MCDONALD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>2359</xocs:ref-first-fp>
            <xocs:ref-last-lp>2374</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref62">
            <xocs:ref-normalized-surname>FRISCH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>GAUSSIAN09REVISIONA02</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sref63">
            <xocs:ref-normalized-surname>WONDROUSCH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1605</xocs:ref-first-fp>
            <xocs:ref-last-lp>1610</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref64"/></xocs:ref-info>
         <xocs:ref-info refid="sref65">
            <xocs:ref-normalized-surname>TOURE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>4711</xocs:ref-first-fp>
            <xocs:ref-last-lp>4723</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref66">
            <xocs:ref-normalized-surname>ZHU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1932</xocs:ref-first-fp>
            <xocs:ref-last-lp>1940</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref67">
            <xocs:ref-normalized-surname>FRIESNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>1739</xocs:ref-first-fp>
            <xocs:ref-last-lp>1749</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref68">
            <xocs:ref-normalized-surname>JACOBSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>351</xocs:ref-first-fp>
            <xocs:ref-last-lp>367</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>PETRIX2020X112836</xocs:refkey3>
         <xocs:refkey4ai>PETRIX2020X112836XL</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="1" is-open-archive="0">Full</xocs:oa-article-status>
         <xocs:oa-access-effective-date>2020-09-10T07:59:46Z</xocs:oa-access-effective-date>
         <xocs:oa-sponsor>
            <xocs:oa-sponsor-type>FundingBody</xocs:oa-sponsor-type>
            <xocs:oa-sponsor-name>Hungary Institutes</xocs:oa-sponsor-name>
         </xocs:oa-sponsor>
         <xocs:oa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:oa-user-license>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2022-09-22T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2022-09-22T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-license-lines>
            <xocs:cp-license-line lang="en">This is an open access article under the CC BY-NC-ND license.</xocs:cp-license-line>
         </xocs:cp-license-lines>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2020 The Author(s). Published by Elsevier Masson SAS.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2020-09-10T07:57:56.508Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency>Nemzeti Kutatási Fejlesztési és Innovációs Hivatal</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100011019</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/719819</xocs:funding-agency-country>
         </xocs:funding>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(20)30808-4</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523420308084</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523420308084</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2020.112836</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2020-11-05T00:58:14.921246Z</xocs:timestamp>
         <xocs:cover-date-start>2020-12-01</xocs:cover-date-start>
         <xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type>
         <xocs:funding-body-id>EISZ</xocs:funding-body-id>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/MAIN/application/pdf/dbb398a6e67865534cfebbfe58d32f58/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>1466192</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>9</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523420308084-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/PREVIEW/image/png/7b98470dd97daa82147ca565cdee6177/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>62449</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/sc1/DOWNSAMPLED/image/jpeg/4c86fd7b9214e68d3cf85de106c8dd10/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>36516</xocs:filesize>
               <xocs:pixel-height>320</xocs:pixel-height>
               <xocs:pixel-width>602</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/gr2/DOWNSAMPLED/image/jpeg/761c8112267f186a211c7604e103ff18/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>52841</xocs:filesize>
               <xocs:pixel-height>418</xocs:pixel-height>
               <xocs:pixel-width>378</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/gr1/DOWNSAMPLED/image/jpeg/68aca418a98351d38b126ef9136a05e5/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>30971</xocs:filesize>
               <xocs:pixel-height>359</xocs:pixel-height>
               <xocs:pixel-width>492</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/fx1/DOWNSAMPLED/image/jpeg/751882da80ade0273208886ae7071d78/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>30221</xocs:filesize>
               <xocs:pixel-height>200</xocs:pixel-height>
               <xocs:pixel-width>308</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/gr3/DOWNSAMPLED/image/jpeg/bfe4d0d4b9f9ba194239ca5ef6871b29/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>36643</xocs:filesize>
               <xocs:pixel-height>149</xocs:pixel-height>
               <xocs:pixel-width>580</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/gr4/DOWNSAMPLED/image/jpeg/9546328c7941a8bf8fdbfbb0221840c0/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>34114</xocs:filesize>
               <xocs:pixel-height>303</xocs:pixel-height>
               <xocs:pixel-width>378</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/gr5/DOWNSAMPLED/image/jpeg/32933ff7269cdc8e40905b58e864c00e/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>61581</xocs:filesize>
               <xocs:pixel-height>409</xocs:pixel-height>
               <xocs:pixel-width>602</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/sc1/THUMBNAIL/image/gif/5298f6b4ebeb38cb563dcce1ddbaeadb/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5070</xocs:filesize>
               <xocs:pixel-height>117</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/gr2/THUMBNAIL/image/gif/09cf95a8244a1a75efc4151fb8aa8a09/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12624</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>148</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/gr1/THUMBNAIL/image/gif/f1faa490ac127bd65f9b49f7762fde83/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5841</xocs:filesize>
               <xocs:pixel-height>160</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/fx1/THUMBNAIL/image/gif/8e2b218eda0c419c1153dd48993f243e/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>19408</xocs:filesize>
               <xocs:pixel-height>142</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/gr3/THUMBNAIL/image/gif/b3d6a24d560e3ad406f7767c9767e49e/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7816</xocs:filesize>
               <xocs:pixel-height>56</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/gr4/THUMBNAIL/image/gif/e591ba4c35d2f2523c675a3570a3319a/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11151</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>204</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/gr5/THUMBNAIL/image/gif/0b05a5cde5e4b71ac2f7ed8c688d0a4f/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11610</xocs:filesize>
               <xocs:pixel-height>149</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-sc1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/sc1/HIGHRES/image/jpeg/2c257113421928fc823cdd34bc612c95/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>292003</xocs:filesize>
               <xocs:pixel-height>1419</xocs:pixel-height>
               <xocs:pixel-width>2666</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/gr2/HIGHRES/image/jpeg/237cdf9a31ef0d5ec2cd90c73cff7622/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>570372</xocs:filesize>
               <xocs:pixel-height>1850</xocs:pixel-height>
               <xocs:pixel-width>1673</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/gr1/HIGHRES/image/jpeg/0bdf6580aeb4f27ea429bcf937c512d9/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>237818</xocs:filesize>
               <xocs:pixel-height>1587</xocs:pixel-height>
               <xocs:pixel-width>2177</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/fx1/HIGHRES/image/jpeg/4e20ad6518f6e8b3f72bba498462563d/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>240480</xocs:filesize>
               <xocs:pixel-height>886</xocs:pixel-height>
               <xocs:pixel-width>1363</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/gr3/HIGHRES/image/jpeg/53ad34fb1fdf9912612098a467ee82e2/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>352751</xocs:filesize>
               <xocs:pixel-height>660</xocs:pixel-height>
               <xocs:pixel-width>2568</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/gr4/HIGHRES/image/jpeg/083fd08452d62bb1b89488c7a995f50b/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>306869</xocs:filesize>
               <xocs:pixel-height>1342</xocs:pixel-height>
               <xocs:pixel-width>1673</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/gr5/HIGHRES/image/jpeg/a43cdf119a52d98292d2916b39864291/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>507519</xocs:filesize>
               <xocs:pixel-height>1812</xocs:pixel-height>
               <xocs:pixel-width>2666</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-mmc1.docx</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420308084/mmc1/MAIN/application/vnd.openxmlformats-officedocument.wordprocessingml.document/1625d99da9a7d818e97d054202b233f0/mmc1.docx</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.docx</xocs:filename>
               <xocs:extension>docx</xocs:extension>
               <xocs:filesize>863085</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420308084-am.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10GK575Z9VK/MAIN/application/pdf/0a741e14ea52cdf40d29368ef9a628d3/am.pdf</xocs:ucs-locator>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>false</xocs:pdf-optimized>
               <xocs:filesize>662414</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>112836</aid>
            <ce:article-number>112836</ce:article-number>
            <ce:pii>S0223-5234(20)30808-4</ce:pii>
            <ce:doi>10.1016/j.ejmech.2020.112836</ce:doi>
            <ce:copyright type="other" year="2020">The Author(s)</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Covalent fragment probes <ce:bold>1</ce:bold>–<ce:bold>24</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0020" role="short">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S0223523420308084/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">Kinases that contain at least one targetable cysteine and are available for testing with the selected enzyme activity assay (Z′-LYTE, Life Technologies), indicated (with red dots) on the kinase phylogenetic tree. Black circles show kinases involved in the mapping. The figure was prepared with the Kinome Render program <ce:cross-ref id="crosref0490" refid="bib46">[46].</ce:cross-ref> (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0025" role="short">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S0223523420308084/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">Radar plots of the inhibitory activities of the covalent fragment library (<ce:bold>1</ce:bold>–<ce:bold>24</ce:bold>).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0030" role="short">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S0223523420308084/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">Radar plot of the inhibitory activity of the covalent fragment library against JAK3 together with the warheads chosen for further analysis.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0035" role="short">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S0223523420308084/gr4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">a) Radar plot of the inhibitory activity of the covalent fragment library against MELK. b) Covalent binding of probe <ce:bold>4</ce:bold> confirmed by <ce:sup loc="post">19</ce:sup>F NMR. c) MELK inhibitory activity of compound <ce:bold>30</ce:bold> and its noncovalent control (<ce:bold>32</ce:bold>). d) Proposed binding mode of compound <ce:bold>30</ce:bold> at the ATP site of MELK.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0040" role="short">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S0223523420308084/gr5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">Synthetic routes to the designed covalent JAK3 inhibitors: (a) Key intermediates <ce:bold>25</ce:bold>–<ce:bold>26</ce:bold> were prepared by Suzuki coupling; (b) synthesis of cyano-acrylamide <ce:bold>30</ce:bold>; and (c) synthesis of amides <ce:bold>31</ce:bold>–<ce:bold>32</ce:bold>. d) Covalent JAK3 inhibitors (<ce:bold>33</ce:bold>, <ce:bold>34</ce:bold>) retrieved retrospectively.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0045" role="short">Scheme 1</ce:alt-text>
               <ce:link locator="sc1" xlink:href="pii:S0223523420308084/sc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Research paper</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">An electrophilic warhead library for mapping the reactivity and accessibility of tractable cysteines in protein kinases</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523420308084-6f6f97757679f5e8538101d4721e90cd">
                  <ce:given-name>László</ce:given-name>
                  <ce:surname>Petri</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523420308084-9854e91fa78844f2df68d19c96384aca">
                  <ce:given-name>Attila</ce:given-name>
                  <ce:surname>Egyed</ce:surname>
                  <ce:cross-ref id="crosref0015" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523420308084-7feb7c050c591264754ce5da34e8f911">
                  <ce:given-name>Dávid</ce:given-name>
                  <ce:surname>Bajusz</ce:surname>
                  <ce:cross-ref id="crosref0020" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523420308084-2f0ee9410c936b1a1c9fa66806e33aba">
                  <ce:given-name>Tímea</ce:given-name>
                  <ce:surname>Imre</ce:surname>
                  <ce:cross-ref id="crosref0025" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au5" author-id="S0223523420308084-dd0c9b167d8a01b62fcbc90e33096b36">
                  <ce:given-name>Anasztázia</ce:given-name>
                  <ce:surname>Hetényi</ce:surname>
                  <ce:cross-ref id="crosref0030" refid="aff3">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au6" orcid="0000-0003-3168-8066" author-id="S0223523420308084-809340d362b490245064c2e9e2a63bdb">
                  <ce:given-name>Tamás</ce:given-name>
                  <ce:surname>Martinek</ce:surname>
                  <ce:cross-ref id="crosref0035" refid="aff3">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au7" author-id="S0223523420308084-bd62255f41f950ff66189e0ebd246825">
                  <ce:given-name>Péter</ce:given-name>
                  <ce:surname>Ábrányi-Balogh</ce:surname>
                  <ce:cross-ref id="crosref0040" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au8" author-id="S0223523420308084-ca7d14b8d7b639baef1d15fcbe870833">
                  <ce:given-name>György M.</ce:given-name>
                  <ce:surname>Keserű</ce:surname>
                  <ce:cross-ref id="crosref0045" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0050" refid="cor1">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523420308084-6c97eebaf3e1062cc3657d1e49c10333">
                  <ce:label>a</ce:label>
                  <ce:textfn>Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Magyar Tudósok Krt 2, H-1117, Budapest, Hungary</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Medicinal Chemistry Research Group</sa:organization>
                     <sa:organization>Research Centre for Natural Sciences</sa:organization>
                     <sa:address-line>Magyar Tudósok Krt 2</sa:address-line>
                     <sa:city>Budapest</sa:city>
                     <sa:postal-code>H-1117</sa:postal-code>
                     <sa:country>Hungary</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Magyar Tudosok Krt 2, H-1117 Budapest, Hungary</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S0223523420308084-f8c1785cd20051004b36136c0f42938b">
                  <ce:label>b</ce:label>
                  <ce:textfn>MS Metabolomics Research Group, Research Centre for Natural Sciences, Magyar Tudósok Krt 2, H-1117, Budapest, Hungary</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>MS Metabolomics Research Group</sa:organization>
                     <sa:organization>Research Centre for Natural Sciences</sa:organization>
                     <sa:address-line>Magyar Tudósok Krt 2</sa:address-line>
                     <sa:city>Budapest</sa:city>
                     <sa:postal-code>H-1117</sa:postal-code>
                     <sa:country>Hungary</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">MS Metabolomics Research Group, Research Centre for Natural Sciences, Magyar Tudosok Krt 2, H-1117 Budapest, Hungary</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff3" affiliation-id="S0223523420308084-516e253aa8f2fa55d6f9b9337b350d1c">
                  <ce:label>c</ce:label>
                  <ce:textfn>Department of Medicinal Chemistry, University of Szeged, Dóm Tér 8, H-6720, Szeged, Hungary</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Medicinal Chemistry</sa:organization>
                     <sa:organization>University of Szeged</sa:organization>
                     <sa:address-line>Dóm Tér 8</sa:address-line>
                     <sa:city>Szeged</sa:city>
                     <sa:postal-code>H-6720</sa:postal-code>
                     <sa:country>Hungary</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0020">MTA-SZTE Biomimetic Systems Research Group, University of Szeged, Dom Ter 8, H-6720 Szeged, Hungary</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
            </ce:author-group>
            <ce:date-received day="11" month="11" year="2019"/></ce:date-received>
            <ce:date-revised day="3" month="9" year="2020"/></ce:date-revised>
            <ce:date-accepted day="7" month="9" year="2020"/></ce:date-accepted>
            <ce:abstract id="abs0010" xml:lang="en" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">Targeted covalent inhibitors represent a viable strategy to block protein kinases involved in different disease pathologies. Although a number of computational protocols have been published for identifying druggable cysteines, experimental approaches are limited for mapping the reactivity and accessibility of these residues. Here, we present a ligand based approach using a toolbox of fragment-sized molecules with identical scaffold but equipped with diverse covalent warheads. Our library represents a unique opportunity for the efficient integration of warhead-optimization and target-validation into the covalent drug development process. Screening this probe kit against multiple kinases could experimentally characterize the accessibility and reactivity of the targeted cysteines and helped to identify suitable warheads for designed covalent inhibitors. The usefulness of this approach has been confirmed retrospectively on Janus kinase 3 (JAK3). Furthermore, representing a prospective validation, we identified Maternal embryonic leucine zipper kinase (MELK), as a tractable covalent target. Covalently labelling and biochemical inhibition of MELK would suggest an alternative covalent strategy for MELK inhibitor programs.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text id="alttext0010" role="short">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:href="pii:S0223523420308084/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords id="kwrds0010" xml:lang="en" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>Warhead selection</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Kinase cysteome profiling</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Targeted covalent inhibitors</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Small-molecule kinase inhibitors</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0030">
                  <ce:text>JAK3</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0035">
                  <ce:text>MELK</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0035" view="all">Medicinal chemistry programs investigating covalent inhibitors have come of age in the last decade [<ce:cross-ref id="crosref0055" refid="bib1">1</ce:cross-ref>,<ce:cross-ref id="crosref0060" refid="bib2">2</ce:cross-ref>]. Intensive targeted covalent inhibitor (TCI) development in oncology has resulted in <ce:italic>afatinib</ce:italic> (Gilotrif®) [<ce:cross-ref id="crosref0065" refid="bib3">3</ce:cross-ref>], an EGFR inhibitor that suppress the growth and proliferation of tumor cells. It was a true milestone in cancer therapy, and became the first FDA-approved covalent small-molecule kinase inhibitor in 2013. Covalent small-molecule kinase inhibitors represent a target-specific subtype of TCIs. Kinases are one of the major classes of signaling proteins that trigger a variety of biochemical processes (e.g. modulating enzyme activity, changing protein conformation, increasing or decreasing stability, activating protein functions) through their phosphorylation [<ce:cross-ref id="crosref0070" refid="bib4">4</ce:cross-ref>]. Kinase signaling pathways are involved in various diseases, like immune disorders, cardiovascular and metabolic diseases and most importantly a large number of different cancers [<ce:cross-ref id="crosref0075" refid="bib5">5</ce:cross-ref>,<ce:cross-ref id="crosref0080" refid="bib6">6</ce:cross-ref>]. Consequently, there has been a high demand for the design and development of kinase inhibitors, particularly in the field of oncology [<ce:cross-ref id="crosref0085" refid="bib7">7</ce:cross-ref>]. Over the past few years, approximately 40 kinases have been pursued as potential targets [<ce:cross-ref id="crosref0090" refid="bib8">8</ce:cross-ref>], but only few targeted covalent inhibitors have received FDA approval: e.g. <ce:italic>afatinib</ce:italic> [<ce:cross-ref id="crosref0095" refid="bib3">3</ce:cross-ref>] (Gilotrif®), <ce:italic>osimertinib</ce:italic> [<ce:cross-ref id="crosref0100" refid="bib9">9</ce:cross-ref>] (Tagrisso®), <ce:italic>neratinib</ce:italic> [<ce:cross-ref id="crosref0105" refid="bib10">10</ce:cross-ref>] (Nerlynx®) and <ce:italic>dacomitinib</ce:italic> [<ce:cross-ref id="crosref0110" refid="bib11">11</ce:cross-ref>] (Vizimpro®) targeting EGFR, or <ce:italic>acalabrutinib</ce:italic> [<ce:cross-ref id="crosref0115" refid="bib12">12</ce:cross-ref>] (Calquence®) and <ce:italic>ibrutinib</ce:italic> [<ce:cross-ref id="crosref0120" refid="bib13">13</ce:cross-ref>] (Imbruvica®) targeting BTK.</ce:para>
                  <ce:para id="p0040" view="all">TCI molecules consist of two main parts: in addition to the noncovalent drug-like scaffold, they are equipped with an appropriate electrophilic warhead [<ce:cross-refs id="crosrefs0010" refid="bib14 bib15 bib16 bib17 bib18">14–18</ce:cross-refs>]. In addition to the optimization of noncovalent interactions, rational design of the warhead moiety is of utmost importance [<ce:cross-ref id="crosref0125" refid="bib19">19</ce:cross-ref>,<ce:cross-ref id="crosref0130" refid="bib20">20</ce:cross-ref>]. The different location and surroundings of the targeted cysteine influence its reactivity and accessibility through changes in the protonation state, the spatial arrangement of the reacting groups, the geometries of the transition states, the intermediates and the product of the covalent bond-forming reaction [<ce:cross-ref id="crosref0135" refid="bib21">21</ce:cross-ref>]. These factors distinguish between the labeling properties of the cysteine residues. In fact, recent proteomic studies have suggested that cysteine reactivity might be remarkably diverse in distinct proteins [<ce:cross-ref id="crosref0140" refid="bib22">22</ce:cross-ref>]. Thus, selecting the appropriate warhead first requires assessment of the reactivity and accessibility of the targeted cysteine [<ce:cross-ref id="crosref0145" refid="bib23">23</ce:cross-ref>]. The available experimental methodologies to evaluate the tractability of cysteines are using activity-based protein profiling (ABPP) [<ce:cross-ref id="crosref0150" refid="bib22">22</ce:cross-ref>,<ce:cross-ref id="crosref0155" refid="bib24">24</ce:cross-ref>,<ce:cross-ref id="crosref0160" refid="bib25">25</ce:cross-ref>] These are all proteomic-level screening techniques performed on living cells and require a powerful MS/MS platform. Even with this high-end instrumentation, other factors, such as the diversity of targets, influence of unknown cellular proteins, and low abundance of the modified protein make the detection of protein adducts in a complex matrix challenging. The only alternatives are computational techniques that have been used for the identification and characterization of reactive cysteines [<ce:cross-refs id="crosrefs0015" refid="bib26 bib27 bib28 bib29 bib30 bib31 bib32">26–32</ce:cross-refs>]. Compilation of targetable cysteines across the human kinome has inspired various research groups, and attempts have been carried out using X-ray based [<ce:cross-ref id="crosref0165" refid="bib33">33</ce:cross-ref>], sequence-based [<ce:cross-ref id="crosref0170" refid="bib34">34</ce:cross-ref>] and interaction fingerprint-based methodologies [<ce:cross-ref id="crosref0175" refid="bib27">27</ce:cross-ref>]. In addition to their position and accessibility, the protonation state of the cysteine thiol has a major influence on its reactivity. Recent articles evaluating cysteine pK<ce:inf loc="post">a</ce:inf> values include a statistical analysis by Zhang et al. [<ce:cross-ref id="crosref0180" refid="bib29">29</ce:cross-ref>] and a sophisticated computational study by Awoonor-Williams and Rowley [<ce:cross-ref id="crosref0185" refid="bib26">26</ce:cross-ref>]. These studies suggest that the targeted cysteines should have a relatively low pK<ce:inf loc="post">a</ce:inf> value, so that the more nucleophilic thiolate form will dominate [<ce:cross-ref id="crosref0190" refid="bib35">35</ce:cross-ref>].</ce:para>
                  <ce:para id="p0045" view="all">Here we introduce a ligand-based technique for mapping cysteine reactivity and accessibility by screening a set of covalent fragments with diverse reactivity. Furthermore, the best performing warheads might serve as a viable starting point for fragment-based optimization aiming to develop targeted covalent inhibitors [<ce:cross-ref id="crosref0195" refid="bib36">36</ce:cross-ref>,<ce:cross-ref id="crosref0200" refid="bib37">37</ce:cross-ref>]. Although several comparative studies have been published on warhead reactivity [<ce:cross-refs id="crosrefs0020" refid="bib38 bib39 bib40">38–40</ce:cross-refs>], our library of warheads equipped to the same scaffold represents a unique opportunity for the efficient integration of warhead optimization into the covalent drug development process. In our preliminary study we found that a smaller proof-of-concept library covered a wide range of reactivity in surrogate assays [<ce:cross-ref id="crosref0205" refid="bib41">41</ce:cross-ref>]. Screening of the extended library described herein against protein kinases provides experimental reactivity and accessibility data of the targeted cysteines.</ce:para>
               </ce:section>
               <ce:section id="sec2" role="results" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Results and discussion</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">Design and characterization of the covalent fragment library</ce:section-title>
                     <ce:para id="p0050" view="all">A ligand-based cysteine mapping technique requires a carefully designed toolbox of covalent probes. Thus, first we intended to compile a preconceived set of fragments suitable for the assessment of the targeted cysteines <ce:italic>via</ce:italic> protein-level biochemical assays. Focusing on the covalent action we kept the noncovalent moiety small and apolar to minimize the noncovalent interaction contribution to fragment binding [<ce:cross-ref id="crosref0210" refid="bib42">42</ce:cross-ref>]. Thus, we chose the 3,5-bis(trifluoromethyl)phenyl scaffold, which showed no interference with any of the assay components, was stable in the assay conditions, provided easy detection by HPLC-MS and <ce:sup loc="post">19</ce:sup>F NMR, and furthermore, the electron withdrawing character of the trifluoromethyl substituents could activate the electrophilic center of the warheads. In total, we selected 24 covalent fragments (<ce:bold>1</ce:bold>-<ce:bold>24</ce:bold>) (<ce:cross-ref id="crosref0215" refid="fig1">Fig. 1</ce:cross-ref>
                        <ce:float-anchor refid="fig1"/></ce:float-anchor>) representing different levels of size and complexity. In addition, the flexibility of the warheads had also a large variety depending on the double or triple bonds, the direct C–C connection or binding through an amide bond or a methylene group to the aromatic ring. The library members or their corresponding intermediates were obtained from commercial sources or by synthesis (for the synthesis details see Supplementary Methods).</ce:para>
                     <ce:para id="p0055" view="all">Assessing the electrophilic character of the probes, we calculated the local electrophilicity index [<ce:cross-ref id="crosref0220" refid="bib43">43</ce:cross-ref>]. These data showed that the library covers a wide range of theoretical electrophilicity (local EPI values of −0.148 for the least and of 0.581 for the most electrophilic probe). For the experimental confirmation, we have tested the probe library in a GSH-reactivity assay [<ce:cross-ref id="crosref0225" refid="bib39">39</ce:cross-ref>,<ce:cross-ref id="crosref0230" refid="bib44">44</ce:cross-ref>] (<ce:cross-ref id="crosref0235" refid="appsec1">Supplementary Table S1</ce:cross-ref>). Nine fragments showed weak reactivity (k<ce:inf loc="post">GSH</ce:inf> < 0.01 h<ce:sup loc="post">−1</ce:sup> for <ce:bold>7</ce:bold>, <ce:bold>8</ce:bold>, <ce:bold>13</ce:bold>–<ce:bold>16</ce:bold>, <ce:bold>18</ce:bold>, <ce:bold>19</ce:bold> and <ce:bold>24</ce:bold>), seven fragments had moderate reactivity (0.01 < k<ce:inf loc="post">GSH</ce:inf> < 0.5 h<ce:sup loc="post">−1</ce:sup> for <ce:bold>1</ce:bold>, <ce:bold>3</ce:bold>, <ce:bold>9</ce:bold>, <ce:bold>17</ce:bold>, <ce:bold>21</ce:bold>, <ce:bold>22</ce:bold>, <ce:bold>23</ce:bold>) and additional seven fragments (<ce:bold>2</ce:bold>, <ce:bold>5</ce:bold>, <ce:bold>6</ce:bold>, <ce:bold>10</ce:bold>, <ce:bold>11</ce:bold>, <ce:bold>12</ce:bold>, <ce:bold>20</ce:bold>) were found to be highly reactive in the GSH assay. There were some warheads that showed similar reactivities (e.g. <ce:bold>8</ce:bold>, <ce:bold>14</ce:bold>, <ce:bold>18</ce:bold> and <ce:bold>1</ce:bold>, <ce:bold>17</ce:bold>); however, their labeling mechanisms are quite different and therefore either might be preferred at certain cysteine targets [<ce:cross-ref id="crosref0240" refid="bib21">21</ce:cross-ref>]. The cysteine selectivity of the applied covalent fragments was confirmed in our recently introduced oligopeptide assay [<ce:cross-ref id="crosref0245" refid="bib44">44</ce:cross-ref>]. As cysteine reactivity can be highly influenced by its environment in a particular protein, the broad spectrum of chemical reactivities and labeling mechanisms might significantly support the mapping efficiency of the probe library. Thus, this specific covalent fragment library could be a useful chemical toolbox for experimental mapping of the reactivity and accessibility of targeted cysteines.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">Mapping the reactivity of kinase cysteines</ce:section-title>
                     <ce:para id="p0060" view="all">As differences in the active sites of kinases influence the reactivity and accessibility of the targeted cysteines, we proposed to map the cysteine reactivity profile of main kinase families. The target kinases were selected as therapeutically significant and already covalently targeted members of the kinase phylogenetic tree that provides good coverage of the human kinome based on their inferred evolutionary relationships (<ce:cross-ref id="crosref0250" refid="fig2">Fig. 2</ce:cross-ref>
                        <ce:float-anchor refid="fig2"/></ce:float-anchor>) [<ce:cross-ref id="crosref0255" refid="bib45">45</ce:cross-ref>].</ce:para>
                     <ce:para id="p0065" view="all">Taking into account the availability of covalently tractable cysteine residues [<ce:cross-ref id="crosref0260" refid="bib27">27</ce:cross-ref>], four kinases were picked up from different branches. We selected BTK from the TK (tyrosine kinase) branch, ERK2 from the CMGC (containing the families CDK, MAPK, GSK3 and CLK) branch, RSK2 from the AGC (containing the families PKA, PKG and PKC) branch and MAP2K6 from the STE (yeast sterile 7-,11- and 20-homologous kinases) branch. Known covalent inhibitors of the selected kinases are summarized in <ce:cross-ref id="crosref0265" refid="appsec1">Supplementary Information Table S2</ce:cross-ref> according to their major warhead chemotypes. The mapping library (<ce:bold>1</ce:bold>–<ce:bold>24</ce:bold>) was screened on the four kinases. Kinase activity was assessed at a concentration of 100 μM of each fragment with the selected kinases (BTK, ERK2, RSK2, MAP2K6) after 60 min of incubation in duplicate. The results of the activity profiling are shown as radar plots in <ce:cross-ref id="crosref0270" refid="fig3">Fig. 3</ce:cross-ref>
                        <ce:float-anchor refid="fig3"/></ce:float-anchor> (for detailed results, see <ce:cross-ref id="crosref0275" refid="appsec1">Supplementary Table S3</ce:cross-ref>).</ce:para>
                     <ce:para id="p0070" view="all">As expected, different targets showed different activity profile. Particularly, of the 24 covalent fragments, <ce:bold>5</ce:bold>, <ce:bold>6</ce:bold>, <ce:bold>12</ce:bold> and <ce:bold>23</ce:bold> displayed high activities (≥70%) across the whole panel, while consistently low inhibition values (<50%) were determined for <ce:bold>3</ce:bold>, <ce:bold>9</ce:bold>, <ce:bold>14</ce:bold>, <ce:bold>15</ce:bold>, <ce:bold>16</ce:bold>, <ce:bold>18</ce:bold> and <ce:bold>24</ce:bold>. The remaining thirteen fragments represent the discriminatory power of the various warhead chemistries among the kinases in the panel. Some have a clear preference for one of the kinases, such as <ce:bold>13</ce:bold> (RSK2) or <ce:bold>19</ce:bold> (BTK), while others display various patterns among the panel, such as <ce:bold>8</ce:bold> (RSK2) or <ce:bold>22</ce:bold> (active against all but ERK2). It has been observed that the intrinsic reactivity overcame the impact of the warhead size. For instance, the bulky maleimides (<ce:bold>5</ce:bold> and <ce:bold>6</ce:bold>), although they are among the largest warheads in this study, performed exceedingly on all investigated kinases. On the contrary, the <ce:bold>12</ce:bold> isothiocyanate, which is less influenced by steric factors, also performed remarkably well. In spite of these examples, the sterically least hindered warheads, such as the styrene (<ce:bold>13</ce:bold>), the acetylene (<ce:bold>14</ce:bold>) or the nitrile (<ce:bold>15</ce:bold>), but also the larger <ce:italic>Boc</ce:italic>-protected hydrazine (<ce:bold>16</ce:bold>) did not show significant inhibition of any of the kinases. However, the smallest warhead, fluorine (<ce:bold>22</ce:bold>) showed quite diverse reactivity profile, while the second smallest warhead, thiol (<ce:bold>23</ce:bold>) resulted in high inhibition activity on all of the kinases. Moreover, it seems that the biological activity was mainly influenced by the warhead chemistry and the common scaffold provided low contribution to the inhibition potency. This is underlined by the comparison of the appropriate compounds: <ce:bold>1</ce:bold>, <ce:bold>5</ce:bold>, <ce:bold>14</ce:bold> and <ce:bold>24</ce:bold>. Compound <ce:bold>1</ce:bold> is equipped with a widely used warhead (acrylamide) that shows specific inhibition against BTK, while it has no significant biological activity on the other 3 kinase targets (ERK2, RSK2 and MAP2K6). This suggests that not only reactivity differences but selectivity issues can be addressed directly to the warhead chemistry. In addition, fragment <ce:bold>5</ce:bold> equipped with a highly reactive maleimide warhead – used extensively in protein labelling studies – inhibit all of the targets. Finally, fragments <ce:bold>14</ce:bold> and <ce:bold>24</ce:bold> carrying the acetylene and the aldehyde function, respectively, that have limited cysteine-reactivity [<ce:cross-ref id="crosref0280" refid="bib17">17</ce:cross-ref>,<ce:cross-ref id="crosref0285" refid="bib47">47</ce:cross-ref>] did not show significant inhibition against any of the targets, however it has the same scaffold as used for all the library members. We found that changing the chlorine to bromine in the warhead, however, leads to increased inhibition against BTK (39% with <ce:bold>16</ce:bold> → 94% with <ce:bold>17</ce:bold>), suggesting that small changes can influence the activity significantly while keeping the noncovalent core unchanged. It is important to note that different warhead chemistries represent various degrees of reactivity and different transition state/product geometries, while the location and the environment of the cysteines adds another layer of diversity that also influences the overall results.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.3" view="all">
                     <ce:label>2.3</ce:label>
                     <ce:section-title id="sectitle0050">Retrospective validation on JAK3</ce:section-title>
                     <ce:para id="p0075" view="all">JAK3 was chosen as potential target for retrospective validation. Noteworthy, the active site of the JAK family is highly conserved, thus selectively achieving ATP-competitive inhibition is challenging. However, a non-conserved cysteine (Cys909) residue is located near the ATP binding site of JAK3, while no vulnerable nucleophilic residue can be found at the active sites of other JAK-subtypes. This unique feature makes JAK3 tractable and alluring for covalent inhibitor programs [<ce:cross-refs id="crosrefs0025" refid="bib48 bib49 bib50 bib51 bib52">48–52</ce:cross-refs>]. Sequence analysis (<ce:cross-ref id="crosref0290" refid="appsec1">Supplementary Table S4</ce:cross-ref>) showed that BTK has the most similar active site to JAK3. As a first step of validation, we screened the mapping library against JAK3 and compared the reactivity profile to that of BTK (<ce:cross-ref id="crosref0295" refid="fig4">Fig. 4</ce:cross-ref>
                        <ce:float-anchor refid="fig4"/></ce:float-anchor> and <ce:cross-ref id="crosref0300" refid="appsec1">Supplementary Table S3</ce:cross-ref>). We found that the calculated reactivity and accessibility of the JAK3 active site cysteine (<ce:cross-ref id="crosref0305" refid="appsec1">Supplementary Table S4</ce:cross-ref>) was by far the closest to BTK based on the calculated pK<ce:inf loc="post">a</ce:inf> values and H-bond contributions, as well as the accessibility (solvent-exposed surface area, SASA) of the cysteines. Consequently, the results of ligand based cysteine reactivity mapping are in line with the sequential and structural similarity of the two kinases. Upon analyzing the inhibition profiles of JAK3 and BTK, after excluding the promiscuous warheads, we concluded that the warheads of probes <ce:bold>1</ce:bold>, <ce:bold>4</ce:bold>, <ce:bold>17</ce:bold> and <ce:bold>19</ce:bold> (acrylamide, cyano-acrylamide, chloroacetamide and 2-bromopropanamide, respectively) could provide the best affinity and selectivity for JAK3 compounds (<ce:cross-ref id="crosref0310" refid="fig4">Fig. 4</ce:cross-ref>). Covalent labeling of the Cys909 residue with the <ce:bold>1</ce:bold> and <ce:bold>17</ce:bold> probes was confirmed by MS/MS studies after digestion of the incubated protein samples (<ce:cross-ref id="crosref0315" refid="appsec1">Supplementary Fig. S1</ce:cross-ref>).</ce:para>
                     <ce:para id="p0080" view="all">Next, we challenged our warhead selection strategy by using the chosen warheads on a well-established hinge binder scaffold, 4-phenyl-pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidine that is utilized by many kinase inhibitors [<ce:cross-ref id="crosref0320" refid="bib49">49</ce:cross-ref>,<ce:cross-refs id="crosrefs0030" refid="bib52 bib53 bib54">52–54</ce:cross-refs>]. This scaffold is providing a synthetically feasible option for warhead optimization. The synthesis of the compounds was carried out in two main steps starting with the preparation of the appropriate intermediates (<ce:bold>25</ce:bold>–<ce:bold>26</ce:bold>, <ce:cross-ref id="crosref0325" refid="sch1">Scheme 1</ce:cross-ref>
                        <ce:float-anchor refid="sch1"/></ce:float-anchor>a) directly prepared by the Suzuki coupling of 4-chloro-1<ce:italic>H</ce:italic>-pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidine (<ce:bold>27</ce:bold>) and the properly substituted phenylboronic acid (<ce:bold>28</ce:bold>–<ce:bold>29</ce:bold>) [<ce:cross-ref id="crosref0330" refid="bib52">52</ce:cross-ref>]. Cyano-acrylamide <ce:bold>30</ce:bold> was derived from <ce:bold>25</ce:bold> aldehyde by Knoevenagel condensation [<ce:cross-ref id="crosref0335" refid="bib55">55</ce:cross-ref>] (<ce:cross-ref id="crosref0340" refid="sch1">Scheme 1</ce:cross-ref>b), while compounds <ce:bold>31</ce:bold> and <ce:bold>32</ce:bold> were synthesized from <ce:bold>26</ce:bold> amine by the corresponding acylation (<ce:cross-ref id="crosref0345" refid="sch1">Scheme 1</ce:cross-ref>c). In addition, to confirm the significant contribution of the covalent interaction to the inhibition, we decided to investigate <ce:bold>32</ce:bold> noncovalent control containing the same scaffold equipped with an acetamide functional group instead of an electrophilic warhead.</ce:para>
                     <ce:para id="p0085" view="all">Introducing the selected warheads from fragments <ce:bold>1</ce:bold> and <ce:bold>17</ce:bold> led to known covalent JAK3 inhibitors <ce:bold>33</ce:bold> and <ce:bold>34</ce:bold> (<ce:cross-ref id="crosref0350" refid="sch1">Scheme 1</ce:cross-ref>d) having low nanomolar or even subnanomolar IC<ce:inf loc="post">50</ce:inf> (0.77 and 1.02 nM, respectively) [<ce:cross-ref id="crosref0355" refid="bib54">54</ce:cross-ref>]. Notably, <ce:bold>33</ce:bold> acrylamide was confirmed to bind JAK3 ATP-site covalently through Cys909 [<ce:cross-ref id="crosref0360" refid="bib52">52</ce:cross-ref>]. The <ce:bold>30</ce:bold> cyano-acrylamide derived from fragment <ce:bold>4</ce:bold> showed some activity against MAP2K6 and RSK2 [<ce:cross-ref id="opt86uu2GDUUk" refid="bib56">56</ce:cross-ref>] (281 and 399 nM, respectively) but blocked JAK3 more effectively (IC<ce:inf loc="post">50</ce:inf> = 55.9 nM). Finally, using the haloacetamide warhead of fragment <ce:bold>19</ce:bold> resulted in a novel covalent JAK3 inhibitor (<ce:bold>31</ce:bold>) with an IC<ce:inf loc="post">50</ce:inf> = 10.6 nM (<ce:cross-ref id="crosref0365" refid="sch1">Scheme 1</ce:cross-ref>).</ce:para>
                     <ce:para id="p0090" view="all">Using the most effective warheads identified by screening our probe library we confirmed that noncovalent interactions are not solely responsible for the selectivity and specificity of covalent inhibitors. Compounds <ce:bold>30,31,33</ce:bold> and <ce:bold>34</ce:bold> differ from <ce:bold>32</ce:bold> only in the presence of an electrophilic warhead suggesting that the covalent interaction contributes significantly to the observed activity (IC<ce:inf loc="post">50</ce:inf> = 832 nM for <ce:bold>32</ce:bold> and 0.77–55.9 nM for <ce:bold>30</ce:bold>, <ce:bold>31</ce:bold>, <ce:bold>33</ce:bold>, <ce:bold>34</ce:bold>). Furthermore, introducing the selected warheads to a hinge binder scaffold, we successfully retrieved already known JAK3 inhibitors (<ce:bold>33</ce:bold> and <ce:bold>34</ce:bold>) and identified two additional compounds with low-nanomolar activity (<ce:bold>30</ce:bold> and <ce:bold>31</ce:bold>). Our results suggest that the mapping of active site cysteines in other kinase targets provides useful information on the reactivity and accessibility of the targeted residue and could help in finding the appropriate warheads for targeted covalent inhibitors.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.4" view="all">
                     <ce:label>2.4</ce:label>
                     <ce:section-title id="sectitle0055">Prospective validation on MELK</ce:section-title>
                     <ce:para id="p0095" view="all">Promising results obtained during the retrospective validation of the cysteine mapping protocol prompted us to apply this strategy prospectively to identify other potential targets for covalent drug discovery programs. For this purpose, we chose MELK kinase which has recently been emerged as an active research target in various oncology-related indications [<ce:cross-refs id="crosrefs0035" refid="bib57 bib58 bib59 bib60 bib61">57–61</ce:cross-refs>]. Noteworthy, to the best of our knowledge, no validated covalent inhibitor for MELK has been disclosed yet. Therefore, we decided to analyze the tractability of MELK applying the ligand-based mapping technique presented herein. The activity profile is shown in <ce:cross-ref id="crosref0370" refid="fig5">Fig. 5</ce:cross-ref>
                        <ce:float-anchor refid="fig5"/></ce:float-anchor>a (for detailed results see <ce:cross-ref id="crosref0375" refid="appsec1">Supplementary Table S3</ce:cross-ref>) that suggested three suitable warheads for covalent targeting of MELK including the <ce:bold>4</ce:bold> cyano-acrylamide, the <ce:bold>11</ce:bold> isothiocyanate and the <ce:bold>20</ce:bold> bromoacetophenone warheads. Motivated by the high fluorine content of the probes, covalent labelling was confirmed by <ce:sup loc="post">19</ce:sup>F NMR measurements (<ce:cross-ref id="crosref0380" refid="fig5">Fig. 5</ce:cross-ref>b). In fact, fragments have been incubated with the isolated MELK protein, and the change in the <ce:sup loc="post">19</ce:sup>F NMR shifts has been followed for 24 h. Comparing the spectra with the protein-free reference, probes <ce:bold>4</ce:bold>, <ce:bold>11</ce:bold> and <ce:bold>20</ce:bold> were proven to label covalently MELK (<ce:cross-ref id="crosref0385" refid="appsec1">Supplementary Fig. S2</ce:cross-ref>) with the labelling efficiency of 97%, 30% and 60%, respectively. We have chosen the most potent warhead chemotype (particularly the cyano-acrylamide, <ce:bold>4</ce:bold>), and together with the general hinge binder scaffold, we tested the previously synthesized analogue (<ce:bold>30</ce:bold>) against MELK (<ce:cross-ref id="crosref0390" refid="fig5">Fig. 5</ce:cross-ref>c).</ce:para>
                     <ce:para id="p0100" view="all">Measuring the activity on MELK we found that <ce:bold>30</ce:bold> is an effective inhibitor (IC<ce:inf loc="post">50</ce:inf> = 25.5 nM, <ce:cross-ref id="crosref0395" refid="fig5">Fig. 5</ce:cross-ref>c), while the noncovalent control <ce:bold>32</ce:bold> resulted in a magnitude higher IC<ce:inf loc="post">50</ce:inf> (222 nM, <ce:cross-ref id="crosref0400" refid="fig5">Fig. 5</ce:cross-ref>c). The order of magnitude difference between the IC<ce:inf loc="post">50</ce:inf> data suggests the significant contribution of the covalent interaction. Although the exact site of labelling could not be identified by preliminary MS/MS experiments, computational analysis identified two tractable cysteines [<ce:cross-ref id="crosref0405" refid="bib27">27</ce:cross-ref>]. One of these residues are located in the hinge region at position Hinge-2 (Cys89), the other sits in the hydrophobic subpocket at position Beta-4-2 (Cys70). Covalent docking of <ce:bold>30</ce:bold> to the ATP site of MELK suggests the latter as the potential site of labelling (<ce:cross-ref id="crosref0410" refid="fig5">Fig. 5</ce:cross-ref>d).</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0060">Conclusion</ce:section-title>
                  <ce:para id="p0105" view="all">Here we provided a novel and readily available ligand based alternative for the experimental characterization of tractable cysteines and target-specific selection of electrophilic warheads. We showed that screening a small library of electrophiles provides reactivity and accessibility information on targeted cysteines, which might be useful identifying tractable targets for covalent inhibition. Our approach selects proper warheads for noncovalent kinase inhibitor scaffolds turning them into covalent inhibitors. The approach has been first challenged in a retrospective validation with JAK3. Testing the probe library we selected suitable JAK3 warheads and then equipped these to a known hinge binder core fragment (4-phenyl-pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidine). This design strategy resulted in four covalent inhibitors, two known compounds were retrieved and two further compounds were identified as novel covalent JAK3 inhibitors. The usefulness of our cysteine profiling strategy has been confirmed prospectively on MELK as a target. Screening the probe library suggested three potential warheads and their covalent binding was subsequently confirmed by <ce:sup loc="post">19</ce:sup>F NMR measurements. Using the most effective cyano-acrylamide warhead, we identified a novel covalent MELK inhibitor with low-nanomolar activity. Based on the success of both the retrospective and prospective application we suggest screening the probe library to evaluate the accessibility and reactivity of targeted cysteines in protein kinases and to select potential warheads for developing novel covalent inhibitors. The probe library is available in physical form from the authors upon request. Considering the significant efforts invested to discover new warhead chemotypes, we plan to include these new warheads in the next edition of the probe library.</ce:para>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0065">Experimental section</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0070">Instruments</ce:section-title>
                     <ce:para id="p0110" view="all">
                        <ce:sup loc="post">1</ce:sup>H NMR spectra were recorded in DMSO‑<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf> or CDCl<ce:inf loc="post">3</ce:inf> solution at room temperature, on a Varian Unity Inova 500 spectrometer (500 MHz for <ce:sup loc="post">1</ce:sup>H NMR spectra), with the deuterium signal of the solvent as the lock and TMS as the internal standard. Chemical shifts (<ce:italic>δ</ce:italic>) and coupling constants (<ce:italic>J</ce:italic>) are given in ppm and Hz, respectively.</ce:para>
                     <ce:para id="p0115" view="all">
                        <ce:sup loc="post">19</ce:sup>F NMR measurements were performed using a 500 MHz Bruker Avance NEO spectrometer equipped with a 5 mm Prodigy BBO probe with z-gradient at 298 K.</ce:para>
                     <ce:para id="p0120" view="all">HPLC-MS measurements were performed using a Shimadzu LCMS-2020 device equipped with a Reprospher 100C18 (5 μm; 100 × 3mm) column and positive-negative double ion source (DUIS±) with a quadrupole MS analyzator in a range of 50–1000 <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>. Sample was eluted with gradient elution using eluent A (10 mM ammonium formate in water:acetonitrile 19:1) and eluent B (10 mM ammonium formate in water:acetonitrile 1:4). Flow rate was set to 1 ml/min. The initial condition was 0% B eluent, followed by a linear gradient to 100% B eluent by 1 min, from 1 to 3.5 min 100% B eluent was retained; and from 3.5 to 4.5 min back to initial condition with 5% B eluent and retained to 5 min. The column temperature was kept at room temperature and the injection volume was 10 μl. Purity of compounds was assessed by HPLC with UV detection at 215 nm; all tested compounds were >95% pure.</ce:para>
                     <ce:para id="p0125" view="all">A Sciex 6500 QTRAP triple quadrupole – linear ion trap mass spectrometer, equipped with a Turbo V Source in electrospray mode (Sciex, CA, USA) and a PerkinElmer Series 200 micro LC system (Massachusetts, USA) consisting of binary pump and an autosampler was used for LC–MS/MS analysis. Data acquisition and processing were performed using Analyst software version 1.6.2 (AB Sciex Instruments, CA, USA). Chromatographic separation was achieved by Purospher STAR RP-18 endcapped (50 mm × 2,1 mm, 3 μm) LiChocart® 55-2 HPLC Cartridge. Sample was eluted with gradient elution using solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid in acetonitrile). Flow rate was set to 0.5 ml/min. The initial condition was 5% B for 2 min, followed by a linear gradient to 95% B by 6 min, from 6 to 8 min 95% B was retained; and from 8 to 8.5 min back to initial condition with 5% eluent B and retained to 14.5 min. The column temperature was kept at room temperature and the injection volume was 10 μl. Nitrogen was used as the nebulizer gas (GS1), heater gas (GS2), and curtain gas with the optimum values set at 35, 45 and 45 (arbitrary units), respectively. The source temperature was 450 °C and the ion spray voltage set at 5000 V. Declustering potential value was set to 150 V.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0075">Local electrophilicity (local EPI) calculations</ce:section-title>
                     <ce:para id="p0130" view="all">Full geometry optimizations and frequency analyses of DFT calculations were carried out in implicit aqueous solution at the B3LYP/6–311++G(2d,2p) level of theory using the Gaussian 09 program package [<ce:cross-ref id="crosref0415" refid="bib62">62</ce:cross-ref>]. Chemical descriptors were calculated from the optimized structures as described in the literature [<ce:cross-ref id="crosref0420" refid="bib43">43</ce:cross-ref>,<ce:cross-ref id="crosref0425" refid="bib63">63</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec4.3" view="all">
                     <ce:label>4.3</ce:label>
                     <ce:section-title id="sectitle0080">GSH reactivity assay</ce:section-title>
                     <ce:para id="p0135" view="all">For thiol reactivity determination recently published assay was applied [<ce:cross-ref id="crosref0430" refid="bib41">41</ce:cross-ref>,<ce:cross-ref id="crosref0435" refid="bib44">44</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec4.4" view="all">
                     <ce:label>4.4</ce:label>
                     <ce:section-title id="sectitle0085">Oligopeptide selectivity assay</ce:section-title>
                     <ce:para id="p0140" view="all">For residue selectivity determination, a recently puplished nonapeptide assay was applied [<ce:cross-ref id="crosref0440" refid="bib44">44</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec4.5" view="all">
                     <ce:label>4.5</ce:label>
                     <ce:section-title id="sectitle0090">Kinase activity assays</ce:section-title>
                     <ce:para id="p0145" view="all">Fragments <ce:bold>1</ce:bold>–<ce:bold>24</ce:bold> were tested at 100 μM in duplicate data points with the Z′-LYTE kinase inhibition assay (Life Technologies). The assay employs a fluorescence-based format and is based on the different sensitivity of phosphorylated and non-phosphorylated peptides to proteolytic cleavage. A suitable peptide substrate is labeled with two fluorophores, forming a FRET pair. After 1 h preincubation with the test compounds the peptide substrate is added and incubating the kinase + peptide + test compound mixture for an additional hour, a development reaction is carried out. Any peptide that was not phosphorylated by the kinase is cleaved, disrupting the resonance energy transfer between the FRET pair. The reaction progress is quantified based on the ratio of the detected emission at 445 nm (coumarin) and 520 nm (fluorescein), <ce:italic>i.e.</ce:italic> the ratio of cleaved vs intact peptide. More detailed description of the assay is available on the website of Life Technologies [<ce:cross-ref id="crosref0445" refid="bib64">64</ce:cross-ref>]. IC<ce:inf loc="post">50</ce:inf> values for <ce:bold>30</ce:bold>-<ce:bold>32</ce:bold> compounds were determined from 10 points titration measurements after the same preincubation protocol described above using the SelectScreen™ Biochemical Kinase Profiling Service available at Life Technologies.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.6" view="all">
                     <ce:label>4.6</ce:label>
                     <ce:section-title id="sectitle0095">JAK3 proteomics MS/MS</ce:section-title>
                     <ce:para id="p0150" view="all">To 50 μL of the 12 μM JAK3 stock solution in 20 mM Tris at pH 8.0 with 150 mM NaCl and 2 mM MnCl<ce:inf loc="post">2</ce:inf>, 1 μL of the covalent probes were added from a 100 mM DMSO stock solution, then the mixture was incubated at room temperature for 120 min. After the labelling, the mixture was digested immediately. Briefly 40–50 μL of the sample and 10 μL 0.2% (w/v) RapiGest SF (Waters, Milford, USA) solution buffered with 50 mM ammonium bicarbonate were mixed (pH = 7.8) and 3.3 μL of 45 mM DTT in 100 mM NH<ce:inf loc="post">4</ce:inf>HCO<ce:inf loc="post">3</ce:inf> were added and kept at 37.5 °C for 30 min. After cooling the sample to room temperature, 4.2 μL of 100 mM iodoacetamide in 100 mM NH<ce:inf loc="post">4</ce:inf>HCO<ce:inf loc="post">3</ce:inf> were added and placed in the dark in room temperature for 30 min. The reduced and alkylated protein was then digested by 10 μL (1 mg/mL) trypsin (the enzyme-to-protein ratio was 1: 10) (Sigma, St Louis, MO, USA). The sample was incubated at 37 °C for overnight. To degrade the surfactant, 7 μL of formic acid (500 mM) solution was added to the digested JAK3 sample and it was incubated at 37 °C for 45 min. For LC-MS analysis, the acid treated sample was centrifuged for 5 min at 13 000 rpm. QTRAP 6500 triple quadruple – linear ion trap mass spectrometer, equipped with a Turbo V source in electrospray mode (AB Sciex, CA, USA) and a PerkinElmer Series 200 micro LC system (Massachusetts, USA) was used for LC-MS/MS analysis. Data acquisition and processing were performed using Analyst software version 1.6.2 (AB Sciex Instruments, CA, USA). Chromatographic separation was achieved by using the Vydac 218 TP52 Protein & Peptide C18 column (250 mm × 2.1 mm, 5 μm). The sample was eluted with a gradient of solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid in ACN). The flow rate was set to 0.2 mL min<ce:sup loc="post">−1</ce:sup>. The initial conditions for separation were 5% B for 7 min, followed by a linear gradient to 90% B by 53 min, from 60 to 63 min 90% B is retained; from 64 to 65 min back to the initial conditions with 5% eluent B retained to 70 min. The injection volume was 10 μL (300 pmol on the column). Information Dependent Acquisiton (IDA) LC-MS/MS experiment was used to identify the modified tryptic JAK3 peptide fragments. Enhanced MS scan (EMS) was applied as survey scan and enhanced product ion (EPI) was the dependent scan. The collision energy in EPI experiments was set to rolling collision energy mode, where the actual value was set on the basis of the mass and charge state of the selected ion. Further IDA criteria: ions greater than: 400.000 m/z, which exceeds 106 counts, exclude former target ions for 30 s after 2 occurrences. In EMS and in EPI mode the scan rate was 1000 Da/s as well. Nitrogen was used as the nebulizer gas (GS1), heater gas (GS2), and curtain gas with the optimum values set at 50, 40 and 40 (arbitrary units). The source temperature was 350 °C and the ion spray voltage set at 5000 V. Declustering potential value was set to 150 V. GPMAW 4.2. software and ProteinProspector (<ce:inter-ref id="intref0010" xlink:href="http://prospector.ucsf.edu/prospector/mshome.htm" xlink:type="simple">http://prospector.ucsf.edu/prospector/mshome.htm</ce:inter-ref>) was used to analyze the large number of MS/MS spectra and identify the modified tryptic JAK3 peptides.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.7" view="all">
                     <ce:label>4.7</ce:label>
                     <ce:section-title id="sectitle0100">NMR measurements for MELK</ce:section-title>
                     <ce:para id="p0155" view="all">The MELK protein and the ligands were dissolved in a 10% (v/v) D<ce:inf loc="post">2</ce:inf>O and H<ce:inf loc="post">2</ce:inf>O mixture containing 20 mM Tris buffer (pH 7.6), 150 mM NaCl and 10% glycerine. For the <ce:sup loc="post">19</ce:sup>F measurements, the MELK and the BTF ligands concentrations were 20 and 40 μM, respectively. As a reference, <ce:sup loc="post">19</ce:sup>F experiments were also performed without the target, containing the ligand species alone. All <ce:sup loc="post">19</ce:sup>F NMR spectra were recorded in the range of F −100 to 0 ppm. A delay time (D1) of 1 s was adopted. To maximize sensitivity, 256 scans were collected into 131072 data points. The Bruker pulse program, zg, was used with a receiver gain (RG) of 54. All <ce:sup loc="post">19</ce:sup>F NMR spectra were phased and baseline corrected using the Topspin 4.2 software package (Bruker BioSpin, Rheinstetten, Germany).</ce:para>
                  </ce:section>
                  <ce:section id="sec4.8" view="all">
                     <ce:label>4.8</ce:label>
                     <ce:section-title id="sectitle0105">Covalent docking</ce:section-title>
                     <ce:para id="p0160" view="all">The binding mode of compound <ce:bold>30</ce:bold> in the binding site of MELK (PDB structure 5IH9 [<ce:cross-ref id="optVtn1Sa0umP" refid="bib65">65</ce:cross-ref>]) was modeled with the Covdock workflow of the Schrödinger Suite in the more precise Pose Prediction mode [<ce:cross-ref id="crosref0450" refid="bib66">66</ce:cross-ref>]. Briefly, the workflow consists of (i) non-covalent docking to the binding site with Glide [<ce:cross-ref id="crosref0455" refid="bib67">67</ce:cross-ref>], (ii) formation of the covalent bond between the ligand and the reactive residue, if the geometry of the non-covalent binding pose permits, (iii) minimization of the resulting covalent complex with Prime [<ce:cross-ref id="crosref0460" refid="bib68">68</ce:cross-ref>], and (iv) re-scoring the minimized complex with Glide. Five poses were saved and visually assessed both for Cys70 and for Cys89, with the one in <ce:cross-ref id="crosref0465" refid="fig5">Fig. 5</ce:cross-ref>D proposed as the most plausible binding mode (based on the favorable H-bonding pattern and closeness of the core scaffold to the hinge region).</ce:para>
                  </ce:section>
                  <ce:section id="sec4.9" view="all">
                     <ce:label>4.9</ce:label>
                     <ce:section-title id="sectitle0110">Synthesis</ce:section-title>
                     <ce:section id="sec4.9.1" view="all">
                        <ce:label>4.9.1</ce:label>
                        <ce:section-title id="sectitle0115">General procedure of Suzuki coupling [<ce:cross-ref id="crosref0470" refid="bib52">52</ce:cross-ref>]</ce:section-title>
                        <ce:para id="p0165" view="all">To a solution of 4-chloro-7<ce:italic>H</ce:italic>-pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidine (1 eq.) and boronic acid (1.3 eq.) in dioxane/H<ce:inf loc="post">2</ce:inf>O (5:1), K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (3 eq.) and Pd(PPh<ce:inf loc="post">3</ce:inf>)<ce:inf loc="post">4</ce:inf> (0,1 eq.) were added under Ar. The mixture was heated to 110 °C for 16 h. The mixture was concentrated and water and DCM were added. The resulting mixture was filtered and the filtrate extracted with CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf> (3 ×). The organic layer dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>. The solvent was removed and the crude material purified by reverse phase chromatography (H<ce:inf loc="post">2</ce:inf>O/CH<ce:inf loc="post">3</ce:inf>CN = 10–100%).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.9.2" view="all">
                        <ce:label>4.9.2</ce:label>
                        <ce:section-title id="sectitle0120">3-(7<ce:italic>H</ce:italic>-Pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidin-4-yl)benzaldehyde (25)</ce:section-title>
                        <ce:para id="p0170" view="all">4-Chloro-7<ce:italic>H</ce:italic>-pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidine (<ce:bold>27</ce:bold>) (1.5 g; 9.76 mmol), (3-formylphenyl)boronic acid (<ce:bold>28</ce:bold>) (1.74 g; 11.7 mmol), K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (4.1 g; 29.4 mmol), Pd(PPh<ce:inf loc="post">3</ce:inf>)<ce:inf loc="post">4</ce:inf> (1.25 g; 0.97 mmol) in dioxane/H<ce:inf loc="post">2</ce:inf>O (5:1) 54 ml, 1.27 g (58%) yellow solid was obtained [<ce:cross-ref id="crosref0475" refid="bib1">1</ce:cross-ref>]. <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.33 (s, 1H, NH), 10.17 (s, 1H, CHO), 8.89 (s, 1H, ArH), 8.70 (s, 1H, ArH), 8.50 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 1H, ArH), 8.06 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 1H, ArH), 7.81 (t, <ce:italic>J</ce:italic> = 7.7 Hz, 1H, ArH), 7.71 (d, <ce:italic>J</ce:italic> = 1.6 Hz, 1H, ArH), 6.96 (d, <ce:italic>J</ce:italic> = 3.2 Hz, 1H, ArH) ppm. <ce:sup loc="post">13</ce:sup>C NMR (126 MHz DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 193.62, 154.49, 153.21, 151.35, 139.19, 137.16, 134.61, 130.60, 130.28, 130.24, 128.66, 115.03, 100.22 ppm. HRMS (ESI): (M + H)<ce:sup loc="post">+</ce:sup> calcd. for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">9</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:sup loc="post">+</ce:sup>, 224.0823; found, 224.0819.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.9.3" view="all">
                        <ce:label>4.9.3</ce:label>
                        <ce:section-title id="sectitle0125">3-(7<ce:italic>H</ce:italic>-Pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidin-4-yl)aniline (26) [<ce:cross-ref id="optgiatMgXJWY" refid="bib52">52</ce:cross-ref>]</ce:section-title>
                        <ce:para id="p0175" view="all">To a solution of 4-chloro-7<ce:italic>H</ce:italic>-pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidine (<ce:bold>27</ce:bold>) (1.5 g, 9.76 mmol) and (3-aminophenyl)boronic acid (<ce:bold>29</ce:bold>) (1.8 g, 11.7 mmol) in 54 mL dioxane/H<ce:inf loc="post">2</ce:inf>O (5:1), K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (4.1 g, 29.4 mmol) and Pd(PPh<ce:inf loc="post">3</ce:inf>)<ce:inf loc="post">4</ce:inf> (1.125 g, 0.97 mmol) were added under Ar. The mixture was heated to 110 °C for 16 h. The mixture was concentrated and water and DCM were added. The resulting mixture was filtered and the filtrate extracted with CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf> (3 ×). The organic layer was dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>. The solvent was removed and the crude material purified by reverse phase chromatography (H<ce:inf loc="post">2</ce:inf>O/CH<ce:inf loc="post">3</ce:inf>CN = 10–100%). 610 mg (30%) yellow solid was obtained. <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 13.06 (s, 1H, NH), 9.02 (s, 1H, ArH), 8.11 (s, 1H), 8.05 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H, ArH), 7.93 (d, <ce:italic>J</ce:italic> = 2.7 Hz, 1H, ArH), 7.70 (t, <ce:italic>J</ce:italic> = 7.9 Hz, 1H, ArH), 7.56 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H, ArH), 7.14 (d, <ce:italic>J</ce:italic> = 3.5 Hz, 1H, ArH) ppm.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.9.4" view="all">
                        <ce:label>4.9.4</ce:label>
                        <ce:section-title id="sectitle0130">3-(3-(7<ce:italic>H</ce:italic>-Pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidin-4-yl)phenyl)-2-cyanoacrylamide (30)</ce:section-title>
                        <ce:para id="p0180" view="all">3-(7<ce:italic>H</ce:italic>-Pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidin-4-yl)benzaldehyde (<ce:bold>25</ce:bold>) (223 mg, 1.0 mmol) and 2-cyanoacetamide (<ce:bold>35</ce:bold>) (126 mg, 1.5 mmol) were dissolved in methanol (10 mL). Catalytic NaOH (1 mg, 1%) was added, and the reaction was stirred at 45 °C for 4 h. The reaction was concentrated under vacuum. The residue was purified on reversed phase column chromatography with a mixture of water and acetonitrile as eluent. The product was obtained as colorless oil (58 mg, 20%). <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.32 (s, 1H, NH), 8.85 (s, 1H, ArH), 8.70 (s, 1H, ArH), 8.36 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H, ArH), 8.33 (s, 1H, –CH = ), 8.06 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 1H, ArH), 7.95 (s, 1H, C(O)NH<ce:inf loc="post">2</ce:inf>), 7.76 (m, 2H, ArH and C(O)NH<ce:inf loc="post">2</ce:inf>), 7.68 (d, <ce:italic>J</ce:italic> = 3.3 Hz, 1H, ArH), 7.01 (d, <ce:italic>J</ce:italic> = 3.3 Hz, 1H, ArH) ppm. <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 172.48, 163.17, 154.63, 153.18, 150.75, 139.21, 133.00, 132.54, 131.80, 130.28, 130.07, 128.57, 116.84, 115.00, 107.99, 100.26 ppm. HRMS (ESI): (M + H)<ce:sup loc="post">+</ce:sup> calcd. for C<ce:inf loc="post">16</ce:inf>H<ce:inf loc="post">11</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:sup loc="post">+</ce:sup>, 290.1041; found, 290.1039.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.9.5" view="all">
                        <ce:label>4.9.5</ce:label>
                        <ce:section-title id="sectitle0135">
                           <ce:italic>N</ce:italic>-(3-(7<ce:italic>H</ce:italic>-Pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidin-4-yl)phenyl)-2-bromopropanamide (31)</ce:section-title>
                        <ce:para id="p0185" view="all">To a solution of 3-(7<ce:italic>H</ce:italic>-pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidin-4-yl)aniline (<ce:bold>26</ce:bold>) (210 mg; 1.0 mmol) in 3 ml DCM at 0 °C TEA (417 μl; 3.0 mmol) was added followed by the dropwise addition of 2-bromopropanoil chloride (<ce:bold>36</ce:bold>) (111 μl; 1.1 mmol). After addition, the mixture was stirred at room temperature for 1 h. The solvent was removed, and the crude material purified by flash chromatography (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>/MeOH = 1–5%) to give 175 mg (50%) product as yellow solid. <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.28 (s, 1H, NH), 10.55 (s, 1H, C(O)NH), 8.84 (s, 1H, ArH), 8.57 (s, 1H, ArH), 7.94 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 1H, ArH), 7.75 (d, <ce:italic>J</ce:italic> = 7.3 Hz, 1H, ArH), 7.70 (s, 1H, ArH), 7.56 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H, ArH), 6.95 (s, 1H, ArH), 4.79–4.68 (m, 1H, CHBr), 1.80 (d, <ce:italic>J</ce:italic> = 6.6 Hz, 2H, CH<ce:inf loc="post">3</ce:inf>), 1.66 (d, <ce:italic>J</ce:italic> = 6.6 Hz, 1H, CH<ce:inf loc="post">3</ce:inf>) <ce:sup loc="post">13</ce:sup>C NMR (125 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 168.21, 155.20, 153.15, 151.07, 139.43, 139.34, 129.85, 128.47, 124.28, 121.23, 119.95, 114.90, 100.46, 44.90, 21.83 ppm. HRMS (ESI): (M + H)<ce:sup loc="post">+</ce:sup> calcd. for C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">13</ce:inf>BrN<ce:inf loc="post">4</ce:inf>O<ce:sup loc="post">+</ce:sup>, 345.0350; found, 345.0348.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.9.6" view="all">
                        <ce:label>4.9.6</ce:label>
                        <ce:section-title id="sectitle0140">
                           <ce:italic>N</ce:italic>-(3-(7<ce:italic>H</ce:italic>-Pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidin-4-yl)phenyl)acetamide (32)</ce:section-title>
                        <ce:para id="p0190" view="all">3-(7<ce:italic>H</ce:italic>-pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidin-4-yl)aniline (<ce:bold>26</ce:bold>) (210 mg, 1.0 mmol) was stirred under Ar atmosphere in 5 mL acetic anhydride (<ce:bold>37</ce:bold>) at RT overnight. The reaction mixture was concentrated under vacuum and the crude product was further purified on reversed phase column chromatography with a mixture of water and acetonitrile as eluent. Finally, <ce:bold>32</ce:bold> was obtained as black powder (43 mg, 17%). <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.22 (s, 1H, NH), 10.13 (s, 1H, C(O)NH), 8.81 (s, 1H, ArH), 8.50 (s, 1H, ArH), 7.85 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H, ArH), 7.72 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H, ArH), 7.65 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H, ArH), 7.48 (t, <ce:italic>J</ce:italic> = 7.9 Hz, 1H, ArH), 6.91 (d, <ce:italic>J</ce:italic> = 2.7 Hz, 1H, ArH), 2.08 (s, 3H, CH<ce:inf loc="post">3</ce:inf>) ppm. <ce:sup loc="post">13</ce:sup>C NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 168.99, 155.66, 153.09, 151.25, 140.10, 138.69, 129.59, 128.12, 123.46, 120.82, 119.62, 114.89, 100.42, 24.50 ppm. HRMS (ESI): (M + H)<ce:sup loc="post">+</ce:sup> calcd. for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">12</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:sup loc="post">+</ce:sup>, 253.1089; found, 253.1085.</ce:para>
                     </ce:section>
                  </ce:section>
               </ce:section>
               <ce:section id="sec5" view="all">
                  <ce:section-title id="sectitle0145">Author contributions</ce:section-title>
                  <ce:para id="p0195" view="all">L.P. and A.E. synthesized electrophilic fragments and covalent inhibitors. L.P. performed the theoretical calculations, the GSH assay, the nonapeptide assay, the JAK3 labelling experiments and wrote the manuscript in part. D.B was involved in computational studies and corresponding data analysis and wrote the manuscript in part. T.I. performed the oligopeptide assay analysis and the JAK3 proteomics MS/MS measurements. A.H. and T.M. performed the NMR measurements for MELK. P.Á.B. designed and supervised the syntheses and wrote the manuscript in part. G.M.K conceived and supervised the project, analyzed and interpreted data, and wrote the manuscript.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0010" view="all">
               <ce:section-title id="sectitle0150">Declaration of competing interest</ce:section-title>
               <ce:para id="p0200" view="all">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0155">Acknowledgement</ce:section-title>
               <ce:para id="p0205" view="all">This work was supported by the National Research, Development and Innovation Office of Hungary (<ce:grant-sponsor id="gs1" sponsor-id="https://doi.org/10.13039/501100011019" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">NKFIH</ce:grant-sponsor> grant number <ce:grant-number refid="gs1">K116904</ce:grant-number>). P. Ábrányi-Balogh was supported by the postdoctoral fellowship of the <ce:grant-sponsor id="gs2" sponsor-id="https://doi.org/10.13039/501100010024" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Hungarian Science Foundation</ce:grant-sponsor> OTKA (<ce:grant-number refid="gs2">PD124598</ce:grant-number>) grant. The work of D. Bajusz is supported by the János Bolyai Research Scholarship of the <ce:grant-sponsor id="gs3" sponsor-id="https://doi.org/10.13039/501100003825" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Hungarian Academy of Sciences</ce:grant-sponsor>. The authors are grateful to Balázs Merő (RCNS) for the expression of MELK, Zoltán Kele (SZTE) for his contribution to the MS investigation of MELK protein, György G. Ferenczy (RCNS) and Greg Makara (ChemPass) for useful discussions on the manuscript.</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0160">Supplementary data</ce:section-title>
                  <ce:para id="p0210" view="all">The following is the Supplementary data to this article:<ce:display>
                        <ce:e-component id="mmc1">
                           <ce:label>Multimedia component 1</ce:label>
                           <ce:alt-text id="alttext0015" role="short">Multimedia component 1</ce:alt-text>
                           <ce:link locator="mmc1" xlink:href="pii:S0223523420308084/mmc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:type="simple"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0165">Supplementary data</ce:section-title>
                  <ce:para id="p0215" view="all">Supplementary data to this article can be found online at <ce:inter-ref id="intref0015" xlink:href="https://doi.org/10.1016/j.ejmech.2020.112836" xlink:type="simple">https://doi.org/10.1016/j.ejmech.2020.112836</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0175">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Bauer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Discov. Today</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>9</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1061</sb:first-page>
                              <sb:last-page>1073</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.drudis.2015.05.005</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0025">Bauer, R. A. Covalent Inhibitors in Drug Discovery: From Accidental Discoveries to Avoided Liabilities and Designed Therapies. Drug Discov Today 2015, 20 (9), 1061-1073. https://doi.org/10.1016/j.drudis.2015.05.005.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Abdeldayem</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.S.</ce:given-name>
                                 <ce:surname>Raouf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.N.</ce:given-name>
                                 <ce:surname>Constantinescu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Moriggl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Advances in covalent kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Soc. Rev.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <ce:doi>10.1039/C9CS00720B</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">Abdeldayem, A.; Raouf, Y. S.; Constantinescu, S. N.; Moriggl, R.; Gunning, P. T. Advances in Covalent Kinase Inhibitors. Chem Soc Rev 2020. https://doi.org/10.1039/C9CS00720B.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.A.</ce:given-name>
                                 <ce:surname>Miller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Hirsh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cadranel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-M.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.-W.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.-C.</ce:given-name>
                                 <ce:surname>Su</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>5</sb:issue-nr>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>528</sb:first-page>
                              <sb:last-page>538</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/S1470-2045(12)70087-6</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">Miller, V. A.; Hirsh, V.; Cadranel, J.; Chen, Y.-M.; Park, K.; Kim, S.-W.; Zhou, C.; Su, W.-C.; Wang, M.; Sun, Y.; et al. Afatinib versus Placebo for Patients with Advanced, Metastatic Non-Small-Cell Lung Cancer after Failure of Erlotinib, Gefitinib, or Both, and One or Two Lines of Chemotherapy (LUX-Lung 1): A Phase 2b/3 Randomised Trial. Lancet Oncol 2012, 13 (5), 528-538. https://doi.org/10.1016/S1470-2045(12)70087-6.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Cohen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The origins of protein phosphorylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>5</sb:issue-nr>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>E127</sb:first-page>
                              <sb:last-page>E130</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/ncb0502-e127</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">Cohen, P. The Origins of Protein Phosphorylation. Nat Cell Biol 2002, 4 (5), E127-E130. https://doi.org/10.1038/ncb0502-e127.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Grant</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic protein kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell. Mol. Life Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>66</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>7</sb:issue-nr>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1163</sb:first-page>
                              <sb:last-page>1177</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/s00018-008-8539-7</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">Grant, S. K. Therapeutic Protein Kinase Inhibitors. Cell Mol Life Sci 2009, 66 (7), 1163-1177. https://doi.org/10.1007/s00018-008-8539-7.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Gharwan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Groninger</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Kinase inhibitors and monoclonal antibodies in oncology: clinical implications</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>4</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>209</sb:first-page>
                              <sb:last-page>227</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nrclinonc.2015.213</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">Gharwan, H.; Groninger, H. Kinase Inhibitors and Monoclonal Antibodies in Oncology: Clinical Implications. Nat Rev Clin Oncol 2016, 13 (4), 209-227. https://doi.org/10.1038/nrclinonc.2015.213.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Santos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Ursu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gaulton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.P.</ce:given-name>
                                 <ce:surname>Bento</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Donadi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.G.</ce:given-name>
                                 <ce:surname>Bologa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Karlsson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Al-Lazikani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hersey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.I.</ce:given-name>
                                 <ce:surname>Oprea</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A comprehensive map of molecular drug targets</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>19</sb:first-page>
                              <sb:last-page>34</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nrd.2016.230</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">Santos, R.; Ursu, O.; Gaulton, A.; Bento, A. P.; Donadi, R. S.; Bologa, C. G.; Karlsson, A.; Al-Lazikani, B.; Hersey, A.; Oprea, T. I.; et al. A Comprehensive Map of Molecular Drug Targets. Nat Rev Drug Discov 2017, 16 (1), 19-34. https://doi.org/10.1038/nrd.2016.230.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.E.</ce:given-name>
                                 <ce:surname>Bourne</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Progress with covalent small-molecule kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Discov. Today</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>3</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>727</sb:first-page>
                              <sb:last-page>735</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.drudis.2018.01.035</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">Zhao, Z.; Bourne, P. E. Progress with Covalent Small-Molecule Kinase Inhibitors. Drug Discov Today 2018, 23 (3), 727-735. https://doi.org/10.1016/j.drudis.2018.01.035.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Yver</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Osimertinib (AZD9291)—a science-driven, collaborative approach to rapid drug design and development</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1165</sb:first-page>
                              <sb:last-page>1170</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1093/annonc/mdw129</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">Yver, A. Osimertinib (AZD9291)-a Science-Driven, Collaborative Approach to Rapid Drug Design and Development. Ann Oncol 2016, 27 (6), 1165-1170. https://doi.org/10.1093/annonc/mdw129.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.A.</ce:given-name>
                                 <ce:surname>Knight</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Shokat</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting the cancer kinome through polypharmacology</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>130</sb:first-page>
                              <sb:last-page>137</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nrc2787</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">Knight, Z. A.; Lin, H.; Shokat, K. M. Targeting the Cancer Kinome through Polypharmacology. Nat Rev Cancer 2010, 10 (2), 130-137. https://doi.org/10.1038/nrc2787.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Brzezniak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Carter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Giaccone</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dacomitinib, a new therapy for the treatment of non-small cell lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expet Opin. Pharmacother.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>247</sb:first-page>
                              <sb:last-page>253</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1517/14656566.2013.758714</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">Brzezniak, C.; Carter, C. A.; Giaccone, G. Dacomitinib, a New Therapy for the Treatment of Non-Small Cell Lung Cancer. Expert Opin Pharmacother 2013, 14 (2), 247-253. https://doi.org/10.1517/14656566.2013.758714.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Hematol. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>21</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1186/s13045-016-0250-9</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">Wu, J.; Zhang, M.; Liu, D. Acalabrutinib (ACP-196): A Selective Second-Generation BTK Inhibitor. J Hematol Oncol 2016, 9 (1), 21. https://doi.org/10.1186/s13045-016-0250-9.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Scheerens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.-J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.E.</ce:given-name>
                                 <ce:surname>Schultz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Sprengeler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.C.</ce:given-name>
                                 <ce:surname>Burrill</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.V.</ce:given-name>
                                 <ce:surname>Mendonca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Sweeney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.C.K.</ce:given-name>
                                 <ce:surname>Scott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.G.</ce:given-name>
                                 <ce:surname>Grothaus</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ChemMedChem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>58</sb:first-page>
                              <sb:last-page>61</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/cmdc.200600221</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">Pan, Z.; Scheerens, H.; Li, S.-J.; Schultz, B. E.; Sprengeler, P. A.; Burrill, L. C.; Mendonca, R. V.; Sweeney, M. D.; Scott, K. C. K.; Grothaus, P. G.; et al. Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase. ChemMedChem 2007, 2 (1), 58-61. https://doi.org/10.1002/cmdc.200600221.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Baillie</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeted covalent inhibitors for drug design</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Angew. Chem. Int. Ed.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>43</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>13408</sb:first-page>
                              <sb:last-page>13421</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/anie.201601091</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">Baillie, T. A. Targeted Covalent Inhibitors for Drug Design. Angew Chemie Int Ed 2016, 55 (43), 13408-13421. https://doi.org/10.1002/anie.201601091.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Shannon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Weerapana</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Covalent protein modification: the current landscape of residue-specific electrophiles</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>18</sb:first-page>
                              <sb:last-page>26</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.cbpa.2014.10.021</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">Shannon, D. A.; Weerapana, E. Covalent Protein Modification: The Current Landscape of Residue-Specific Electrophiles. Curr Opin Chem Biol 2015, 24, 18-26. https://doi.org/10.1016/j.cbpa.2014.10.021.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Lonsdale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Burgess</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Colclough</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.L.</ce:given-name>
                                 <ce:surname>Davies</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Lenz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Orton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Ward</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Expanding the armory: predicting and tuning covalent warhead reactivity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Inf. Model.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>12</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3124</sb:first-page>
                              <sb:last-page>3137</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jcim.7b00553</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">Lonsdale, R.; Burgess, J.; Colclough, N.; Davies, N. L.; Lenz, E. M.; Orton, A. L.; Ward, R. A. Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity. J Chem Inf Model 2017, 57 (12), 3124-3137. https://doi.org/10.1021/acs.jcim.7b00553.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gehringer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Laufer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Emerging and Re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>12</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5673</sb:first-page>
                              <sb:last-page>5724</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.8b01153</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">Gehringer, M.; Laufer, S. A. Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology. J Med Chem 2019, 62 (12), 5673-5724. https://doi.org/10.1021/acs.jmedchem.8b01153.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Hatcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Teng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kostic</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recent advances in selective and irreversible covalent ligand development and validation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>11</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1486</sb:first-page>
                              <sb:last-page>1500</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.chembiol.2019.09.012</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">Zhang, T.; Hatcher, J. M.; Teng, M.; Gray, N. S.; Kostic, M. Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation. Cell Chem Biol 2019, 26 (11), 1486-1500. https://doi.org/10.1016/j.chembiol.2019.09.012.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Du</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Gu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>CBinderDB: a covalent binding agent database</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioinformatics</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1258</sb:first-page>
                              <sb:last-page>1260</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1093/bioinformatics/btw801</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">Du, J.; Yan, X.; Liu, Z.; Cui, L.; Ding, P.; Tan, X.; Li, X.; Zhou, H.; Gu, Q.; Xu, J. CBinderDB: A Covalent Binding Agent Database. Bioinformatics 2017, 33 (8), 1258-1260. https://doi.org/10.1093/bioinformatics/btw801.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gersch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kreuzer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Sieber</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Electrophilic natural products and their biological targets</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Prod. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>29</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>659</sb:first-page>
                              <sb:last-page>682</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1039/c2np20012k</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">Gersch, M.; Kreuzer, J.; Sieber, S. A. Electrophilic Natural Products and Their Biological Targets. Nat Prod Rep 2012, 29 (6), 659-682. https://doi.org/10.1039/c2np20012k.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>McGregor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Jenkins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Kerwin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Burke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Shokat</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Expanding the scope of electrophiles capable of targeting K-ras oncogenes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochemistry</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>25</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3178</sb:first-page>
                              <sb:last-page>3183</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.biochem.7b00271</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">McGregor, L. M.; Jenkins, M. L.; Kerwin, C.; Burke, J. E.; Shokat, K. M. Expanding the Scope of Electrophiles Capable of Targeting K-Ras Oncogenes. Biochemistry 2017, 56 (25), 3178-3183. https://doi.org/10.1021/acs.biochem.7b00271.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Weerapana</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Simon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Richter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Khare</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.B.D.</ce:given-name>
                                 <ce:surname>Dillon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Bachovchin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Mowen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Baker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.F.</ce:given-name>
                                 <ce:surname>Cravatt</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Quantitative reactivity profiling predicts functional cysteines in proteomes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>468</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>7325</sb:issue-nr>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>790</sb:first-page>
                              <sb:last-page>795</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nature09472</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">Weerapana, E.; Wang, C.; Simon, G. M.; Richter, F.; Khare, S.; Dillon, M. B. D.; Bachovchin, D. A.; Mowen, K.; Baker, D.; Cravatt, B. F. Quantitative Reactivity Profiling Predicts Functional Cysteines in Proteomes. Nature 2010, 468 (7325), 790-795. https://doi.org/10.1038/nature09472.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Backus</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Applications of reactive cysteine profiling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:edited-book>
                              <sb:title>
                                 <sb:maintitle>Current Topics in Microbiology and Immunology</sb:maintitle>
                              </sb:title>
                              <sb:date>2018</sb:date>
                              <sb:publisher>
                                 <sb:name>Springer-Verlag</sb:name>
                                 <sb:location>Berlin, Heidelberg</sb:location>
                              </sb:publisher>
                           </sb:edited-book>
                           <ce:doi>10.1007/82_2018_120</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">Backus, K. M. Applications of Reactive Cysteine Profiling. In Current Topics in Microbiology and Immunology; Springer-Verlag: Berlin, Heidelberg, 2018; p doi: 10.1007/82_2018_120. https://doi.org/10.1007/82_2018_120.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Advanced activity-based protein profiling application strategies for drug development</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>353</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.3389/fphar.2018.00353</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">Wang, S.; Tian, Y.; Wang, M.; Wang, M.; Sun, G.; Sun, X. Advanced Activity-Based Protein Profiling Application Strategies for Drug Development. Front Pharmacol 2018, 9, 353. https://doi.org/10.3389/fphar.2018.00353.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Shiraiwa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Nonaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Tamura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Hamachi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chemical tools for endogenous protein labeling and profiling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>970</sb:first-page>
                              <sb:last-page>985</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.chembiol.2020.06.016</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">Shiraiwa, K.; Cheng, R.; Nonaka, H.; Tamura, T.; Hamachi, I. Chemical Tools for Endogenous Protein Labeling and Profiling. Cell Chem Biol 2020, 27 (8), 970-985. https://doi.org/10.1016/j.chembiol.2020.06.016.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Awoonor-Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.N.</ce:given-name>
                                 <ce:surname>Rowley</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>How reactive are druggable cysteines in protein kinases?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Inf. Model.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>9</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1935</sb:first-page>
                              <sb:last-page>1946</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jcim.8b00454</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">Awoonor-Williams, E.; Rowley, C. N. How reactive are druggable cysteines in protein kinases? J. Chem. Inf. Model. 2018, 58 (9), 1935-1946. https://doi.org/10.1021/acs.jcim.8b00454.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bliven</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.E.</ce:given-name>
                                 <ce:surname>Bourne</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Determining cysteines available for covalent inhibition across the human kinome</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>7</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2879</sb:first-page>
                              <sb:last-page>2889</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.6b01815</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0155">Zhao, Z.; Liu, Q.; Bliven, S.; Xie, L.; Bourne, P. E. Determining Cysteines Available for Covalent Inhibition Across the Human Kinome. J Med Chem 2017, 60 (7), 2879-2889. https://doi.org/10.1021/acs.jmedchem.6b01815.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.-C.</ce:given-name>
                                 <ce:surname>Tsai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Assessing lysine and cysteine reactivities for designing targeted covalent kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Am. Chem. Soc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>141</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>16</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6553</sb:first-page>
                              <sb:last-page>6560</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jacs.8b13248</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">Liu, R.; Yue, Z.; Tsai, C.-C.; Shen, J. Assessing Lysine and Cysteine Reactivities for Designing Targeted Covalent Kinase Inhibitors. J Am Chem Soc 2019, 141 (16), 6553-6560. https://doi.org/10.1021/jacs.8b13248.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Pei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lai</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Statistical analysis and prediction of covalent ligand targeted cysteine residues</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Inf. Model.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1453</sb:first-page>
                              <sb:last-page>1460</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jcim.7b00163</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">Zhang, W.; Pei, J.; Lai, L. Statistical Analysis and Prediction of Covalent Ligand Targeted Cysteine Residues. J Chem Inf Model 2017, 57 (6), 1453-1460. https://doi.org/10.1021/acs.jcim.7b00163.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Murray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Politzer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The electrostatic potential: an overview</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Wiley Interdiscip. Rev. Comput. Mol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>153</sb:first-page>
                              <sb:last-page>163</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/wcms.19</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">Murray, J. S.; Politzer, P. The Electrostatic Potential: An Overview. Wiley Interdiscip Rev Comput Mol Sci 2011, 1 (2), 153-163. https://doi.org/10.1002/wcms.19.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Naray-Szabo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.G.</ce:given-name>
                                 <ce:surname>Ferenczy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular electrostatics</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>95</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>4</sb:issue-nr>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>829</sb:first-page>
                              <sb:last-page>847</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/cr00036a002</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">Naray-Szabo, G.; Ferenczy, G. G. Molecular Electrostatics. Chem Rev 1995, 95 (4), 829-847. https://doi.org/10.1021/cr00036a002.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Cohen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structural bioinformatics-based design of selective, irreversible kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>308</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>80</sb:issue-nr>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1318</sb:first-page>
                              <sb:last-page>1321</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1126/science1108367</ce:doi>
                        </sb:host>
                        <sb:comment>5726</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0180">Cohen, M. S. Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors. Science (80- ) 2005, 308 (5726), 1318-1321. https://doi.org/10.1126/science1108367.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Leproult</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Barluenga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Moras</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-M.</ce:given-name>
                                 <ce:surname>Wurtz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Winssinger</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>5</sb:issue-nr>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1347</sb:first-page>
                              <sb:last-page>1355</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm101396q</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">Leproult, E.; Barluenga, S.; Moras, D.; Wurtz, J.-M.; Winssinger, N. Cysteine Mapping in Conformationally Distinct Kinase Nucleotide Binding Sites: Application to the Design of Selective Covalent Inhibitors. J Med Chem 2011, 54 (5), 1347-1355. https://doi.org/10.1021/jm101396q.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Sabnis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Buhrlage</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.H.</ce:given-name>
                                 <ce:surname>Jones</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Developing irreversible inhibitors of the protein kinase cysteinome</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>146</sb:first-page>
                              <sb:last-page>159</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.chembiol.2012.12.006</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">Liu, Q.; Sabnis, Y.; Zhao, Z.; Zhang, T.; Buhrlage, S. J.; Jones, L. H.; Gray, N. S. Developing Irreversible Inhibitors of the Protein Kinase Cysteinome. Chem Biol 2013, 20 (2), 146-159. https://doi.org/10.1016/j.chembiol.2012.12.006.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Awoonor-Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.</ce:given-name>
                                 <ce:surname>Walsh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.N.</ce:given-name>
                                 <ce:surname>Rowley</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Modeling covalent-modifier drugs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochim. Biophys. Acta Protein Proteonomics</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1865</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>11</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1664</sb:first-page>
                              <sb:last-page>1675</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bbapap.2017.05.009</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0195">Awoonor-Williams, E.; Walsh, A. G.; Rowley, C. N. Modeling Covalent-Modifier Drugs. Biochim Biophys Acta - Proteins Proteomics 2017, 1865 (11), 1664-1675. https://doi.org/10.1016/j.bbapap.2017.05.009.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Erlanson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Fesik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.E.</ce:given-name>
                                 <ce:surname>Hubbard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Jahnke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Jhoti</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Twenty years on: the impact of fragments on drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>9</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>605</sb:first-page>
                              <sb:last-page>619</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nrd.2016.109</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0200">Erlanson, D. A.; Fesik, S. W.; Hubbard, R. E.; Jahnke, W.; Jhoti, H. Twenty Years on: The Impact of Fragments on Drug Discovery. Nat Rev Drug Discov 2016, 15 (9), 605-619. https://doi.org/10.1038/nrd.2016.109.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Keeley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Petri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ábrányi-Balogh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Keserű</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Covalent fragment libraries in drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Discov. Today</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <ce:doi>10.1016/j.drudis.2020.03.016</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0205">Keeley, A.; Petri, L.; Abranyi-Balogh, P.; Keseru, G. M. Covalent Fragment Libraries in Drug Discovery. Drug Discov Today 2020. https://doi.org/10.1016/j.drudis.2020.03.016.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.H.</ce:given-name>
                                 <ce:surname>Krenske</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Petter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.N.</ce:given-name>
                                 <ce:surname>Houk</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Kinetics and thermodynamics of reversible thiol additions to mono- and diactivated michael acceptors: implications for the design of drugs that bind covalently to cysteines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Org. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>81</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>23</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>11726</sb:first-page>
                              <sb:last-page>11733</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.joc.6b02188</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0210">Krenske, E. H.; Petter, R. C.; Houk, K. N. Kinetics and Thermodynamics of Reversible Thiol Additions to Mono- and Diactivated Michael Acceptors: Implications for the Design of Drugs That Bind Covalently to Cysteines. J Org Chem 2016, 81 (23), 11726-11733. https://doi.org/10.1021/acs.joc.6b02188.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Flanagan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Abramite</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Anderson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Aulabaugh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.P.</ce:given-name>
                                 <ce:surname>Dahal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Gilbert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Montgomery</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Oppenheimer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ryder</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>23</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>10072</sb:first-page>
                              <sb:last-page>10079</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm501412a</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0215">Flanagan, M. E.; Abramite, J. A.; Anderson, D. P.; Aulabaugh, A.; Dahal, U. P.; Gilbert, A. M.; Li, C.; Montgomery, J.; Oppenheimer, S. R.; Ryder, T.; et al. Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors. J Med Chem 2014, 57 (23), 10072-10079. https://doi.org/10.1021/jm501412a.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.J.</ce:given-name>
                                 <ce:surname>Cee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.P.</ce:given-name>
                                 <ce:surname>Volak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Bartberger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Tegley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Arvedson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>McCarter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Tasker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Fotsch</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Systematic study of the glutathione (GSH) reactivity of N -arylacrylamides: 1. Effects of aryl substitution</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>23</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9171</sb:first-page>
                              <sb:last-page>9178</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.5b01018</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0220">Cee, V. J.; Volak, L. P.; Chen, Y.; Bartberger, M. D.; Tegley, C.; Arvedson, T.; McCarter, J.; Tasker, A. S.; Fotsch, C. Systematic Study of the Glutathione (GSH) Reactivity of N -Arylacrylamides: 1. Effects of Aryl Substitution. J Med Chem 2015, 58 (23), 9171-9178. https://doi.org/10.1021/acs.jmedchem.5b01018.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Petri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ábrányi-Balogh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.R.</ce:given-name>
                                 <ce:surname>Varga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Imre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Keserű</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Comparative reactivity analysis of small-molecule thiol surrogates</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>7</sb:issue-nr>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>115357</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bmc.2020.115357</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0225">Petri, L.; Abranyi-Balogh, P.; Varga, P. R.; Imre, T.; Keseru, G. M. Comparative Reactivity Analysis of Small-Molecule Thiol Surrogates. Bioorg Med Chem 2020, 28 (7), 115357. https://doi.org/10.1016/j.bmc.2020.115357.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.G.</ce:given-name>
                                 <ce:surname>Ferenczy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Keserű</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Thermodynamics of fragment binding</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Inf. Model.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>52</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>4</sb:issue-nr>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1039</sb:first-page>
                              <sb:last-page>1045</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/ci200608b</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0230">Ferenczy, G. G.; Keseru, G. M. Thermodynamics of Fragment Binding. J Chem Inf Model 2012, 52 (4), 1039-1045. https://doi.org/10.1021/ci200608b.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Chattaraj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Sarkar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Roy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Electrophilicity index</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>106</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2065</sb:first-page>
                              <sb:last-page>2091</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/cr040109f</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0235">Chattaraj, P. K.; Sarkar, U.; Roy, D. R. Electrophilicity Index. Chem Rev 2006, 106 (6), 2065-2091. https://doi.org/10.1021/cr040109f.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ábrányi-Balogh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Petri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Imre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Szijj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Scarpino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hrast</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mitrović</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.P.</ce:given-name>
                                 <ce:surname>Fonovič</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Németh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Barreteau</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A road map for prioritizing warheads for cysteine targeting covalent inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>160</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>94</sb:first-page>
                              <sb:last-page>107</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2018.10.010</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0240">Abranyi-Balogh, P.; Petri, L.; Imre, T.; Szijj, P.; Scarpino, A.; Hrast, M.; Mitrovic, A.; Fonovic, U. P.; Nemeth, K.; Barreteau, H.; et al. A Road Map for Prioritizing Warheads for Cysteine Targeting Covalent Inhibitors. Eur J Med Chem 2018, 160, 94-107. https://doi.org/10.1016/j.ejmech.2018.10.010.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Manning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The protein kinase complement of the human genome</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>298</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>80</sb:issue-nr>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1912</sb:first-page>
                              <sb:last-page>1934</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1126/science.1075762</ce:doi>
                        </sb:host>
                        <sb:comment>5600</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0245">Manning, G. The Protein Kinase Complement of the Human Genome. Science (80- ) 2002, 298 (5600), 1912-1934. https://doi.org/10.1126/science.1075762.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Chartier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Chénard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Barker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Najmanovich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Kinome</ce:given-name>
                                 <ce:surname>Render</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A stand-alone and web-accessible tool to annotate the human protein kinome tree</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PeerJ</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e126</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.7717/peerj.126</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0250">Chartier, M.; Chenard, T.; Barker, J.; Najmanovich, R. Kinome Render: A Stand-Alone and Web-Accessible Tool to Annotate the Human Protein Kinome Tree. PeerJ 2013, 1, e126. https://doi.org/10.7717/peerj.126.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Vasudevan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Argiriadi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Baranczak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Friedman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Gavrilyuk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Hobson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Hulce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Osman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Wilson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Covalent binders in drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:edited-book>
                              <sb:title>
                                 <sb:maintitle>Progress in Medicinal Chemistry</sb:maintitle>
                              </sb:title>
                              <sb:date>2019</sb:date>
                           </sb:edited-book>
                           <ce:doi>10.1016/bs.pmch.2018.12.002</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0255">Vasudevan, A.; Argiriadi, M. A.; Baranczak, A.; Friedman, M. M.; Gavrilyuk, J.; Hobson, A. D.; Hulce, J. J.; Osman, S.; Wilson, N. S. Covalent Binders in Drug Discovery. In Progress in Medicinal Chemistry; 2019. https://doi.org/10.1016/bs.pmch.2018.12.002.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.R.</ce:given-name>
                                 <ce:surname>Goedken</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Argiriadi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Banach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.A.</ce:given-name>
                                 <ce:surname>Fiamengo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Foley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.E.</ce:given-name>
                                 <ce:surname>Frank</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>George</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Harris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Hobson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Ihle</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>290</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4573</sb:first-page>
                              <sb:last-page>4589</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1074/jbc.M114.595181</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0260">Goedken, E. R.; Argiriadi, M. A.; Banach, D. L.; Fiamengo, B. A.; Foley, S. E.; Frank, K. E.; George, J. S.; Harris, C. M.; Hobson, A. D.; Ihle, D. C.; et al. Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol. J Biol Chem 2015, 290 (8), 4573-4589. https://doi.org/10.1074/jbc.M114.595181.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Akahane</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>McNally</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.S.E.</ce:given-name>
                                 <ce:surname>Reyskens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.B.</ce:given-name>
                                 <ce:surname>Ficarro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Herter-Sprie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Koyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Pattison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Labella</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Development of selective covalent Janus kinase 3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>16</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6589</sb:first-page>
                              <sb:last-page>6606</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.5b00710</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0265">Tan, L.; Akahane, K.; McNally, R.; Reyskens, K. M. S. E.; Ficarro, S. B.; Liu, S.; Herter-Sprie, G. S.; Koyama, S.; Pattison, M. J.; Labella, K.; et al. Development of Selective Covalent Janus Kinase 3 Inhibitors. J Med Chem 2015, 58 (16), 6589-6606. https://doi.org/10.1021/acs.jmedchem.5b00710.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kempson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ovalle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.T.</ce:given-name>
                                 <ce:surname>Wrobleski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Spergel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.-W.</ce:given-name>
                                 <ce:surname>Duan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Das</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of highly potent, selective, covalent inhibitors of JAK3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>20</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4622</sb:first-page>
                              <sb:last-page>4625</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bmcl.2017.09.023</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0270">Kempson, J.; Ovalle, D.; Guo, J.; Wrobleski, S. T.; Lin, S.; Spergel, S. H.; Duan, J. J.-W.; Jiang, B.; Lu, Z.; Das, J.; et al. Discovery of Highly Potent, Selective, Covalent Inhibitors of JAK3. Bioorg Med Chem Lett 2017, 27 (20), 4622-4625. https://doi.org/10.1016/j.bmcl.2017.09.023.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref51">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.-B.</ce:given-name>
                                 <ce:surname>Telliez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Dowty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jussif</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Moy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Balbo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>12</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3442</sb:first-page>
                              <sb:last-page>3451</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acschembio.6b00677</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0275">Telliez, J.-B.; Dowty, M. E.; Wang, L.; Jussif, J.; Lin, T.; Li, L.; Moy, E.; Balbo, P.; Li, W.; Zhao, Y.; et al. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over Pan-JAK or JAK1-Selective Inhibition. ACS Chem Biol 2016, 11 (12), 3442-3451. https://doi.org/10.1021/acschembio.6b00677.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib52">
                     <ce:label>[52]</ce:label>
                     <sb:reference id="sref52">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Thorarensen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Dowty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Banker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Juba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jussif</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Vincent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Czerwinski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Casimiro-Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Unwalla</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design of a Janus kinase 3 (JAK3) specific inhibitor 1-((2 S ,5 R )-5-((7 H -Pyrrolo[2,3- d ]Pyrimidin-4-Yl)Amino)-2-Methylpiperidin-1-Yl)Prop-2-En-1-One (PF-06651600) allowing for the interrogation of JAK3 signaling in humans</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>5</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1971</sb:first-page>
                              <sb:last-page>1993</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.6b01694</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0280">Thorarensen, A.; Dowty, M. E.; Banker, M. E.; Juba, B.; Jussif, J.; Lin, T.; Vincent, F.; Czerwinski, R. M.; Casimiro-Garcia, A.; Unwalla, R.; et al. Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2 S ,5 R )-5-((7 H -Pyrrolo[2,3- d ]Pyrimidin-4-Yl)Amino)-2-Methylpiperidin-1-Yl)Prop-2-En-1-One (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans. J Med Chem 2017, 60 (5), 1971-1993. https://doi.org/10.1021/acs.jmedchem.6b01694.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib53">
                     <ce:label>[53]</ce:label>
                     <sb:reference id="sref53">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Forster</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gehringer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Laufer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recent advances in JAK3 inhibition: isoform selectivity by covalent cysteine targeting</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>18</sb:issue-nr>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4229</sb:first-page>
                              <sb:last-page>4237</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bmcl.2017.07.079</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0285">Forster, M.; Gehringer, M.; Laufer, S. A. Recent Advances in JAK3 Inhibition: Isoform Selectivity by Covalent Cysteine Targeting. Bioorg Med Chem Lett 2017, 27 (18), 4229-4237. https://doi.org/10.1016/j.bmcl.2017.07.079.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib54">
                     <ce:label>[54]</ce:label>
                     <sb:reference id="sref54">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Shao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Lan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis, and SAR study of highly potent, selective, irreversible covalent JAK3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Divers.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>343</sb:first-page>
                              <sb:last-page>358</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/s11030-017-9803-2</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0290">He, L.; Shao, M.; Wang, T.; Lan, T.; Zhang, C.; Chen, L. Design, Synthesis, and SAR Study of Highly Potent, Selective, Irreversible Covalent JAK3 Inhibitors. Mol Divers 2018, 22 (2), 343-358. https://doi.org/10.1007/s11030-017-9803-2.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib55">
                     <ce:label>[55]</ce:label>
                     <sb:reference id="sref55">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Gunasekar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Thamaraiselvi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Rathore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.I.</ce:given-name>
                                 <ce:surname>Sathiyanarayanan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Easwaramoorthi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tuning the electronic properties of 2-cyano-3-phenylacrylamide derivatives</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Org. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>80</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>24</sb:issue-nr>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>12351</sb:first-page>
                              <sb:last-page>12358</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.joc.5b02226</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0295">Gunasekar, R.; Thamaraiselvi, P.; Rathore, R. S.; Sathiyanarayanan, K. I.; Easwaramoorthi, S. Tuning the Electronic Properties of 2-Cyano-3-Phenylacrylamide Derivatives. J Org Chem 2015, 80 (24), 12351-12358. https://doi.org/10.1021/acs.joc.5b02226.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib56">
                     <ce:label>[56]</ce:label>
                     <sb:reference id="sref56">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>London</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Miller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Krishnan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Uchida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Irwin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Eidam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Gibold</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Cimermančič</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Bonnet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.K.</ce:given-name>
                                 <ce:surname>Shoichet</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Covalent docking of large libraries for the discovery of chemical probes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>12</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1066</sb:first-page>
                              <sb:last-page>1072</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nchembio.1666</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0300">London, N.; Miller, R. M.; Krishnan, S.; Uchida, K.; Irwin, J. J.; Eidam, O.; Gibold, L.; Cimermancic, P.; Bonnet, R.; Shoichet, B. K.; et al. Covalent Docking of Large Libraries for the Discovery of Chemical Probes. Nat Chem Biol 2014, 10 (12), 1066-1072. https://doi.org/10.1038/nchembio.1666.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib57">
                     <ce:label>[57]</ce:label>
                     <sb:reference id="sref57">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Deng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Saloura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Nakamura</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>MELK inhibition targets cancer stem cells through downregulation of SOX2 expression in head and neck cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncol. Rep.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <ce:doi>10.3892/or.2019.6988</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0305">Ren, L.; Deng, B.; Saloura, V.; Park, J.; Nakamura, Y. MELK Inhibition Targets Cancer Stem Cells through Downregulation of SOX2 Expression in Head and Neck Cancer Cells. Oncol Rep 2019. https://doi.org/10.3892/or.2019.6988.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib58">
                     <ce:label>[58]</ce:label>
                     <sb:reference id="sref58">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Chlenski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Dobratic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>Salwen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Budke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-H.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Miller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Applebaum</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Wilkinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Nakamura</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Maternal embryonic leucine zipper kinase (MELK), a potential therapeutic target for neuroblastoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Canc. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>3</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>507</sb:first-page>
                              <sb:last-page>516</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/1535-7163.MCT-18-0819</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0310">Chlenski, A.; Park, C.; Dobratic, M.; Salwen, H. R.; Budke, B.; Park, J.-H.; Miller, R.; Applebaum, M. A.; Wilkinson, E.; Nakamura, Y.; et al. Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma. Mol Cancer Ther 2019, 18 (3), 507-516. https://doi.org/10.1158/1535-7163.MCT-18-0819.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib59">
                     <ce:label>[59]</ce:label>
                     <sb:reference id="sref59">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Cigliano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Pilo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mela</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ribback</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Dombrowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Pes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Cossu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Evert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.F.</ce:given-name>
                                 <ce:surname>Calvisi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Utpatel</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of MELK protooncogene as an innovative treatment for intrahepatic cholangiocarcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Medicina (B Aires)</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.3390/medicina56010001</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0315">Cigliano, A.; Pilo, M. G.; Mela, M.; Ribback, S.; Dombrowski, F.; Pes, G. M.; Cossu, A.; Evert, M.; Calvisi, D. F.; Utpatel, K. Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma. Medicina (B Aires) 2019, 56 (1), 1. https://doi.org/10.3390/medicina56010001.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib60">
                     <ce:label>[60]</ce:label>
                     <sb:reference id="sref60">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Meel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Guillén Navarro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>de Gooijer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Metselaar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Waranecki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Breur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Lagerweij</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.E.</ce:given-name>
                                 <ce:surname>Wedekind</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Koster</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>van de Wetering</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>MEK/MELK inhibition and blood–brain barrier deficiencies in atypical teratoid/rhabdoid tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neuro Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>1</sb:issue-nr>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>58</sb:first-page>
                              <sb:last-page>69</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1093/neuonc/noz151</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0320">Meel, M. H.; Guillen Navarro, M.; de Gooijer, M. C.; Metselaar, D. S.; Waranecki, P.; Breur, M.; Lagerweij, T.; Wedekind, L. E.; Koster, J.; van de Wetering, M. D.; et al. MEK/MELK Inhibition and Blood-Brain Barrier Deficiencies in Atypical Teratoid/Rhabdoid Tumors. Neuro Oncol 2020, 22 (1), 58-69. https://doi.org/10.1093/neuonc/noz151.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib61">
                     <ce:label>[61]</ce:label>
                     <sb:reference id="sref61">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.M.</ce:given-name>
                                 <ce:surname>McDonald</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.D.</ce:given-name>
                                 <ce:surname>Grant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.P.</ce:given-name>
                                 <ce:surname>East</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.S.K.</ce:given-name>
                                 <ce:surname>Gilbert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Wilkerson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Goldfarb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Beri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.E.</ce:given-name>
                                 <ce:surname>Herring</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Vaziri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.G.</ce:given-name>
                                 <ce:surname>Cook</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mass spectrometry–based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>295</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>8</sb:issue-nr>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2359</sb:first-page>
                              <sb:last-page>2374</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1074/jbc.RA119.011083</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0325">McDonald, I. M.; Grant, G. D.; East, M. P.; Gilbert, T. S. K.; Wilkerson, E. M.; Goldfarb, D.; Beri, J.; Herring, L. E.; Vaziri, C.; Cook, J. G.; et al. Mass Spectrometry-Based Selectivity Profiling Identifies a Highly Selective Inhibitor of the Kinase MELK That Delays Mitotic Entry in Cancer Cells. J Biol Chem 2020, 295 (8), 2359-2374. https://doi.org/10.1074/jbc.RA119.011083.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib62">
                     <ce:label>[62]</ce:label>
                     <sb:reference id="sref62">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Frisch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.B.</ce:given-name>
                                 <ce:surname>Schlegel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.E.</ce:given-name>
                                 <ce:surname>Scuseria</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Gaussian 09 (Revision A.02)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2009</sb:date>
                              <sb:publisher>
                                 <sb:name>Gaussian Inc</sb:name>
                                 <sb:location>Wallingford, CT</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0330">Frisch, M. J.; Schlegel, H. B.; Scuseria, G. E.; et al. Gaussian 09 (Revision A.02). Gaussian Inc, Wallingford, CT, 2009.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib63">
                     <ce:label>[63]</ce:label>
                     <sb:reference id="sref63">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wondrousch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Böhme</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Thaens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ost</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Schüürmann</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Local electrophilicity predicts the toxicity-relevant reactivity of michael acceptors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Phys. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>10</sb:issue-nr>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1605</sb:first-page>
                              <sb:last-page>1610</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jz100247x</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0335">Wondrousch, D.; Bohme, A.; Thaens, D.; Ost, N.; Schuurmann, G. Local Electrophilicity Predicts the Toxicity-Relevant Reactivity of Michael Acceptors. J Phys Chem Lett 2010, 1 (10), 1605-1610. https://doi.org/10.1021/jz100247x.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib64">
                     <ce:label>[64]</ce:label>
                     <sb:reference id="sref64">
                        <sb:contribution langtype="en">
                           <sb:title>
                              <sb:maintitle>Z’-LYTE biochemical kinase assays</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intref0020" xlink:href="http://www.thermofisher.com/hu/en/home/industrial/pharma-biopharma/drug-discovery-development/target-and-lead-identification-and-validation/kinasebiology/kinase-activity-assays.html" xlink:type="simple">http://www.thermofisher.com/hu/en/home/industrial/pharma-biopharma/drug-discovery-development/target-and-lead-identification-and-validation/kinasebiology/kinase-activity-assays.html</ce:inter-ref>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0340">Z’-LYTE Biochemical Kinase Assays: http://www.thermofisher.com/hu/en/home/industrial/pharma-biopharma/drug-discovery-development/target-and-lead-identification-and-validation/kinasebiology/kinase-activity-assays.html.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib65">
                     <ce:label>[65]</ce:label>
                     <sb:reference id="sref65">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.B.</ce:given-name>
                                 <ce:surname>Touré</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Giraldes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.R.</ce:given-name>
                                 <ce:surname>Sprague</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mathieu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Mishina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yan-Neale</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Toward the validation of maternal embryonic leucine zipper kinase: discovery, optimization of highly potent and selective inhibitors, and preliminary biology insight</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>59</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>10</sb:issue-nr>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4711</sb:first-page>
                              <sb:last-page>4723</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.6b00052</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0345">Toure, B. B.; Giraldes, J.; Smith, T.; Sprague, E. R.; Wang, Y.; Mathieu, S.; Chen, Z.; Mishina, Y.; Feng, Y.; Yan-Neale, Y.; et al. Toward the Validation of Maternal Embryonic Leucine Zipper Kinase: Discovery, Optimization of Highly Potent and Selective Inhibitors, and Preliminary Biology Insight. J Med Chem 2016, 59 (10), 4711-4723. https://doi.org/10.1021/acs.jmedchem.6b00052.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib66">
                     <ce:label>[66]</ce:label>
                     <sb:reference id="sref66">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.W.</ce:given-name>
                                 <ce:surname>Borrelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Greenwood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Day</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Abel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Farid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Harder</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Docking covalent inhibitors: a parameter free approach to pose prediction and scoring</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Inf. Model.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>7</sb:issue-nr>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1932</sb:first-page>
                              <sb:last-page>1940</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/ci500118s</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0350">Zhu, K.; Borrelli, K. W.; Greenwood, J. R.; Day, T.; Abel, R.; Farid, R. S.; Harder, E. Docking Covalent Inhibitors: A Parameter Free Approach To Pose Prediction and Scoring. J Chem Inf Model 2014, 54 (7), 1932-1940. https://doi.org/10.1021/ci500118s.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib67">
                     <ce:label>[67]</ce:label>
                     <sb:reference id="sref67">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Friesner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Banks</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.B.</ce:given-name>
                                 <ce:surname>Murphy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Halgren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Klicic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.T.</ce:given-name>
                                 <ce:surname>Mainz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.P.</ce:given-name>
                                 <ce:surname>Repasky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.H.</ce:given-name>
                                 <ce:surname>Knoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Shelley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Perry</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>47</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>7</sb:issue-nr>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1739</sb:first-page>
                              <sb:last-page>1749</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm0306430</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0355">Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; et al. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy. J Med Chem 2004, 47 (7), 1739-1749. https://doi.org/10.1021/jm0306430.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib68">
                     <ce:label>[68]</ce:label>
                     <sb:reference id="sref68">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.P.</ce:given-name>
                                 <ce:surname>Jacobson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Pincus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.S.</ce:given-name>
                                 <ce:surname>Rapp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.F.</ce:given-name>
                                 <ce:surname>Day</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Honig</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Shaw</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Friesner</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A hierarchical approach to all-atom protein loop prediction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proteins Struct. Funct. Bioinforma.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>2</sb:issue-nr>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>351</sb:first-page>
                              <sb:last-page>367</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/prot.10613</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0360">Jacobson, M. P.; Pincus, D. L.; Rapp, C. S.; Day, T. J. F.; Honig, B.; Shaw, D. E.; Friesner, R. A. A Hierarchical Approach to All-Atom Protein Loop Prediction. Proteins Struct Funct Bioinforma 2004, 55 (2), 351-367. https://doi.org/10.1002/prot.10613.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>